<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2504245206
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ELIGARD 22.5 MG POWDER FOR SOLUTION FOR INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEUPRORELIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        22.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder and solvent for solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Restricted
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        796.80
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TOLMAR INC." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TOLMAR INC.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASTELLAS PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02AE02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance of ELIGARD belongs to the group of so-called gonadotropin releasing hormones. These medicines are used to decrease the production of certain sex hormones (testosterone).</p><p>ELIGARD is used to treat hormone dependent metastatic <strong>prostate cancer </strong>in adult men and for the treatment of high-risk non-metastatic hormone dependent prostate cancer in combination with radiotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use ELIGARD</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are a <strong>woman or a child</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>hypersensitive (allergic) </strong>to the active substance leuprorelin acetate, products with an activity comparable to the naturally occurring hormone gonadotropin, or to any of the other ingredients&nbsp; of ELIGARD (listed in&nbsp; section 6).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Following <strong>surgical removal of your testes</strong>, as in that case ELIGARD does not lead to a further decrease in&nbsp; serum testosterone levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; As the only treatment if you suffer from symptoms related to pressure on the spinal cord or tumour in the spinal column. In this case, ELIGARD may only be used in combination with other medicinal products for prostate cancer.</p><p>Warnings&nbsp; and precautions</p><p><strong>Talk&nbsp; to your doctor, pharmacist or nurse before using ELIGARD</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have any of the following: Any heart or blood vessel conditions, including heart rhythm problems (arrhythmia), or are being treated with medicines for these conditions. The risk of heart rhythm problems may be increased when using ELIGARD.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you have <strong>difficulties urinating</strong>. You should be monitored closely during the first weeks of treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If <strong>pressure on the spinal cord or difficulties with urinating develops</strong>. In connection with other drugs having a similar mechanism of action like ELIGARD, it has been reported that severe cases of pressure effects on the spinal cord and narrowing of the tubes between the kidneys and the urinary bladder may contribute to paralysis like symptoms. If these complications develop, standard therapy should be started.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you experience sudden headache, vomiting, altered mental status and sometimes heart collapse, within two weeks of taking ELIGARD, then alert the doctor or medical staff. These are rare cases termed as pituitary apoplexy, which have been reported IN OTHER &nbsp;DRUGS</p><p>which have a mechanism similar&nbsp; to ELIGARD.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from <strong>diabetes mellitus </strong>(elevated blood sugar levels). You should be regularly monitored during treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with ELIGARD can increase the risk for fractures due to osteoporosis (decrease in bone density)<em>.</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; There have been reports of depression in patients taking Eligard. If you are taking Eligard and develop&nbsp; depressed mood, inform your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; There have been reports of cardiovascular events in patients taking products similar to Eligard of which it is unknown if it is related to these products. If you are taking Eligard and develop cardiovascular signs or symptoms, inform your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; There have been reports of seizures in patients after administration of Eligard. If you are taking Eligard&nbsp; and develop&nbsp; seizures, inform your doctor.</p><p>Initial treatment complications</p><p>During the first week of treatment, there is generally a brief increase in the male sex hormone testosterone in the blood. This can lead to <strong>a temporary worsening </strong>in the disease-related symptoms and also to the occurrence of new symptoms that have not been experienced up to this point. These especially include bone pain, urination disturbances, pressure on the spinal cord, or the secretion of blood in the urine. These symptoms usually subside on continuation of treatment. If the symptoms do not subside, you should contact your doctor.</p><p>If ELIGARD&nbsp; does not help</p><p>A proportion of the patients will have tumors, which are not sensitive to decreased serum testosterone levels. Please talk to you doctor if you have the impression that the effect of ELIGARD&nbsp; is too weak.</p><p>Other medicines and ELIGARD</p><p>ELIGARD might interfere with some medicines used to treat heart rhythm problems (e.g. quinidine, procainamide, amiodarone and sotalol) or might increase the risk of heart rhythm problems when used with some other drugs (e.g. methadone (used for pain relief and part of drug addiction detoxification), moxifloxacin (an antibiotic), antipsychotics used for serious mental illnesses).</p><p>Tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including&nbsp; medicines&nbsp; obtained without a prescription.</p><p><strong>Pregnancy and breast-feeding </strong>ELIGARD is not intended for women. <strong>Driving and using machines</strong></p><p>Fatigue, dizziness and visual disturbances arepossibleside effects of thetreatment with ELIGARD or might be a result from the disease. If you suffer from these side effects, take care when driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Dose</p><p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>If not otherwise prescribed by your doctor, ELIGARD 22.5 mg is administered <strong>once </strong>every <strong>three months</strong>.</p><p>The injected solution forms an active substance depot from which a continuous release of the active substance leuprorelin acetate takes place over a period of three months.</p><p>Additional tests</p><p>Response to therapy with ELIGARD should be checked by your doctor by means of checking specific clinical values and by measuring the blood levels of the so-called prostate-specific antigen (PSA).</p><p>Method of administration</p><p>ELIGARD should only be administered by your <strong>doctor </strong>or <strong>a nurse. </strong>They will also take care of the preparation of the ready-to-use solution (according to the instructions given in <em>Section 7</em></p><p><em>Information for Healthcare Professionals</em>, at the end of this leaflet).</p><p>After preparation, ELIGARD is administered as a subcutaneous injection (injection into the tissue below the skin). Intra-arterial (into an artery) or intravenous (into a vein) injection has to be strictly avoided. As&nbsp; with other active substances that are injected subcutaneously, the site of injection should be varied periodically.</p><p>If you receive more ELIGARD than you should</p><p>Since the injection is generally administered by your doctor or appropriately trained staff, over dosage is not to be expected.</p><p>If a larger amount than intended is nevertheless administered, your doctor will monitor you specifically and give you additional&nbsp; treatment as required.</p><p>If the administration of ELIGARD is&nbsp; forgotten</p><p>Please talk to you doctor if you believe that your three monthly administration of ELIGARD was forgotten.</p><p>Effects when the treatment with ELIGARD is&nbsp; stopped</p><p>As a general rule, the therapy of prostate cancer with ELIGARD requires long-term treatment. Therefore, therapy should not be terminated, even if there is an improvement in the symptoms or if they disappear completely.</p><p>If the treatment with ELIGARD is stopped prematurely, a deterioration of disease-related symptoms can occur.</p><p>You should not stop the therapy prematurely without previously consulting your doctor.</p><p><strong>If you have any further question on the use of this medicine, ask your doctor, pharmacist or nurse.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like&nbsp; all&nbsp; medicines, ELIGARD can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Side effects that have been observed during treatment with ELIGARD are mainly attributable to the specific effect of the active substance leuprorelin acetate, namely the increase and decrease of certain hormones. The most commonly described side effects are hot flashes (approximately 58 % of patients), nausea, malaise and fatigue, as well as temporary local irritations&nbsp; at the site of injection.</p><p>&nbsp;</p><p>Initial side effects</p><p><strong>&nbsp;</strong></p><p>During the first weeks of treatment with ELIGARD, disease-specific symptoms may worsen, because in first instance there is generally a brief increase in the male sex hormone testosterone in the blood. Therefore, your doctor may administer an appropriate anti-androgen (substance that inhibits the effect of testosterone) at the initial phase of the treatment in order to reduce possible after-effects <em>(See also Section 2 Before you use ELIGARD, Initial treatment complications)</em>.</p><p>&nbsp;</p><p>Local side effects</p><p><strong>&nbsp;</strong></p><p>Local side effects that have been described after the injection of ELIGARD are typically&nbsp; those,</p><p>which are often associated with similar subcutaneously injected preparations (preparations which are injected into the tissue below the skin). Mild burning immediately after the injection is very common. Stinging and pain after the injection are common, as well as a bruise at the injection site. Redness of the skin at the injection site has been reported commonly. Tissue hardening and ulceration are uncommon.</p><p>&nbsp;</p><p>These local side effects following subcutaneous injection are mild and described as being of brief duration. They do not occur again in between the individual&nbsp; injections.</p><p>&nbsp;</p><p>Very common side effects (may affect more than 1 in 10 people)</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hot flashes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spontaneous bleeding in&nbsp; skin or mucous membrane, redness of the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fatigue, injection-related&nbsp; side effects <em>(see also local side effects above)</em></p><p><em>&nbsp;</em></p><p>Common side effects (may affe ct up to 1 in 10 pe ople )</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nasopharyngitis (symptoms of common&nbsp; cold)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea, malaise, diarrhoea, inflammation of the stomach and intestines (gastroenteritis/ colitis)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching, nightly sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain in&nbsp; the joints,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Irregular trips to the toilet to pass water (also at night), difficulty in starting to pass water, painful urination,&nbsp; reduced urine output</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast tenderness, swelling of the breast, shrinking of testicles, testicular pain, infertility, erectile&nbsp; dysfunction, reduced penis size</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rigors (episodes of exaggerated shaking with high fevers), &nbsp;weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged bleeding time, changes in blood values, decreased red blood cells/low red blood cell count</p><p>&nbsp;</p><p>Uncommon side effects (may affe ct up to 1 in 100 pe ople )</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Urinary tract infection, local skin infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Worsening of diabetes mellitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal dreams, depression, decreased libido</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, headache, an alteration in the skin sensation, insomnia, taste disturbance, smell disturbance</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypertension&nbsp; (increased blood pressure), hypotension (decreased blood &nbsp;pressure)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Constipation, dry mouth, Dyspepsia (disturbed digestion, with symptoms as full stomach, pain&nbsp; in&nbsp; the stomach, belching, nausea, vomiting, burning feeling in&nbsp; the stomach), vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clamminess,&nbsp; increased sweating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Back&nbsp; pain, muscles cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Haematuria&nbsp; (blood in&nbsp; the urine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bladder&nbsp; spasm, more trips to the toilet to pass water than usual, unable to pass &nbsp;water</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Enlargement&nbsp; of male&nbsp; breast tissue, impotence</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lethargy (sleepiness), pain, fever</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased weight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of balance, light-headedness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle wasting/loss of muscle tissue after prolonged use</p><p>&nbsp;</p><p>Rare side effects (may affe ct up to 1 in 1,000 people)</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal involuntary movements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden loss of consciousness, fainting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flatulence, belching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hair&nbsp; loss, skin eruption (pimples on the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Breast pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site ulceration</p><p>&nbsp;</p><p>Very rare side effects (may affect up to 1 in 10,000 people)</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Injection site necrosis</p><p>&nbsp;</p><p>Not&nbsp; known (frequency cannot be&nbsp; estimated from the available data)</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in&nbsp; ECG&nbsp; (QT prolongation)</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Other side effects</p><p><strong>&nbsp;</strong></p><p>Other side effects that have been described in the literature in relation with treatment with leuprorelin, the active substance of ELIGARD, are oedema (accumulation of fluid in&nbsp; tissue, appearing as swelling of the hands and feet), pulmonary embolism (resulting in symptoms like breathlessness, difficulty in breathing and chest pain)<strong>, </strong>palpitations (awareness of your heartbeat), muscle weakness, chills, rash, impaired memory and impaired vision.&nbsp; Increasing signs of a decrease in bone tissue (osteoporosis) may be expected after long-term treatment with ELIGARD. Due to osteoporosis, the risk for fractures increases.</p><p>&nbsp;</p><p>Serious allergic reactions, which cause difficulty in breathing or dizziness, have been reported rarely after administration of products in the same class as&nbsp; Eligard.</p><p>&nbsp;</p><p>Seizures have been reported after administration of products in the same class as&nbsp; Eligard.</p><p>&nbsp;</p><p>Reporting of side effects</p><p><strong>&nbsp;</strong></p><p><strong>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use after the expiry date printed on the outer packaging. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Storage instructions</p><p><strong>&nbsp;</strong></p><p>Store in&nbsp; a refrigerator (2&deg;C - 8&deg;C).</p><p>Store in&nbsp; the original&nbsp; package in&nbsp; order to protect from moisture.</p><p>&nbsp;</p><p>This product must be at room temperature prior to injection. Remove from the refrigerator approximately 30 minutes before use. Once outside the refrigerator this product may be stored in its original&nbsp; packaging at room temperature (below 25&deg;C) for up to four weeks.</p><p>&nbsp;</p><p>Once the tray has been opened, the product must be prepared straight away and the product must be used immediately.&nbsp; For single use only.</p><p>&nbsp;</p><p>Instructions on disposal of unused or expired ELIGARD packs</p><p><strong>&nbsp;</strong></p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer&nbsp; required. These measures will help&nbsp; to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is&nbsp; leuprorelin acetate.</p><p>One pre-filled&nbsp; syringe (Syringe B)&nbsp; contains 22.5 mg leuprorelin acetate.</p><p>&nbsp;</p><p>The other ingredients are Poly(DL-lactic-co-glycolic-acid) (75:25) and N-methyl-2-pyrrolidone in the pre-filled&nbsp; syringe with solution for injection&nbsp; (Syringe A).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                ELIGARD is a powder and solvent for solution for injection. ELIGARD  22.5 mg is available  in  the following packs
•	A thermoformed tray pack consisting of two thermoformed trays in a cardboard carton. One tray contains pre-filled syringe A, a large plunger rod for syringe B and a desiccant pouch. The other tray contains pre-filled  syringe B,  a 20-gauge sterile needle and a desiccant pouch.

•	A bundle pack containing kits of 2 x 2 pre-filled syringes (1 x Syringe A; 1 x Syringe B) Not all  pack sizes may be available.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and&nbsp; Manufacturer</p><p>Astellas Pharma Europe B.V. Sylviusweg 62</p><p>2333 BE Leiden The Netherlands</p><p>&nbsp;</p><p>Manufacturer</p><p>Tolmar Inc.</p><p>701 Centre Avenue Ft. Collins, CO 80526 USA</p><p>&nbsp;</p><p>Cangene bioPharma Inc. 1111 South Paca Street Baltimore, MD 21230 USA</p><p>&nbsp;</p><p>Manufacturer responsible for batch release</p><p><u>Manufacturing license holder </u>Astellas Pharma Europe B.V. Sylviusweg 62</p><p>2333 BE Leiden The Netherlands</p><p>&nbsp;</p><p><u>Manufacturing site</u></p><p>Astellas Pharma Europe B.V. Hogemaat 2</p><p>7942 JG Meppel The Netherlands</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in November 2017.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>&nbsp;</strong></p><p dir="RTL">ﺗﻨﺘﻤﻲ اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔﻓﻲ دواء&nbsp;ELIGARD&nbsp;إﻟﻰ اﻟﻤﺠﻤﻮﻋﺔ اﻟﺘﻲ ﯾﻄﻠﻖ ﻋﻠﯿﮭﺎ اﺳﻢ اﻟﮭﺮﻣﻮﻧﺎت اﻟ&nbsp;ُﻤﺤﻔﺰة ﻹﻓﺮاز ھﺮﻣﻮن اﻟﻐﺪد اﻟﺘﻨﺎﺳﻠﯿﺔ</p><p dir="RTL">اﻟﺠﻮﻧﺎدوﺗﺮوﻓﯿﻦ. وﺗﺴﺘﺨﺪَم ھﺬه اﻷدوﯾﺔ ﻟﺘﻘﻠﯿﻞ إﻓﺮاز ھﺮﻣﻮﻧﺎت ﺗﻨﺎﺳﻠﯿﺔ ﻣﻌﯿﻨﺔ )اﻟﺘﺴﺘﻮﺳﺘﯿﺮون.(</p><p>&nbsp;</p><p dir="RTL">وﯾﺴﺘﺨﺪَم دواء&nbsp;ELIGARD&nbsp;ﻟﻌﻼج ﺳﺮطﺎن اﻟﺒﺮوﺳﺘﺎﺗﺎ اﻟﻨﻘﯿﻠﻲ اﻟﻤﻌﺘﻤﺪ ﻋﻠﻰ اﻟﮭﺮﻣﻮﻧﺎتﻓﻲ اﻟﺮﺟﺎل اﻟﺒﺎﻟﻐﯿﻦ وﻟﻌﻼج<strong> ﺳﺮطﺎن اﻟﺒﺮوﺳﺘﺎﺗﺎ</strong> ﻏﯿﺮ</p><p dir="RTL">اﻟﻨﻘﯿﻠﻲ اﻟﻌﺎﻟﻲ اﻟﺨﻄﻮرة اﻟﻤﻌﺘﻤﺪ ﻋﻠﻰ اﻟﮭﺮﻣﻮﻧﺎت ﺑﺎﻟﺪﻣﺞ ﻣﻊ اﻟﻌﻼج اﻹﺷﻌﺎﻋﻲ.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL"><strong>ﻻ ﯾﺠﺐ اﺳﺘﺨﺪام</strong><strong> ELIGARD</strong><strong> ﻓﻲ اﻟﺤﺎﻻت اﻟﺘﺎﻟﯿﺔ</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻣﻊ<strong> اﻟﺴﯿﺪات أو اﻷطﻔﺎل</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ<strong> ﺣﺴﺎﺳﯿﺔ ﻣﻔﺮطﺔ</strong> ﺿﺪ ﻣﺎدة أﺳﯿﺘﺎت اﻟﻠﯿﻮﺑﺮورﻟﯿﻦ اﻟﻔﻌﺎﻟﺔ أو اﻟﻤﻨﺘﺠﺎت اﻟﺘﻲ ﺗﺤﺪث ﻧﺸﺎطًﺎ ﺷﺒﯿ&nbsp;&nbsp; ًﮭﺎ&nbsp;ﺑﺎﻟﺬي ﯾﺤﺪﺛﮫ</p><p dir="RTL">اﻟﮭﺮﻣﻮن اﻟﻤﻨﺸﻂ ﻟﻠﻐﺪد اﻟﺘﻨﺎﺳﻠﯿﺔ اﻟﺠﻮﻧﺎدوﺗﺮوﻓﯿﻦ طﺒﯿﻌﯿًﺎ أو أي ﻣﻦ اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى اﻟﺘﻲ ﯾﺤﺘﻮﯾﮭﺎ دواء ELIGARD )اﻟﻤﺪرﺟﺔ</p><p dir="RTL">ﻓﻲ اﻟﻘﺴﻢ .(6 &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺑﻌﺪ<strong> </strong><strong>اﺳﺘﺌﺼﺎل</strong><strong> </strong><strong>اﻟﺨﺼﯿﺘﯿﻦ ﺑﺎﻟﺠﺮاﺣﺔ</strong>، ﺣﯿﺚ إﻧﮫﻓﻲ ﺗﻠﻚ اﻟﺤﺎﻟﺔ ﻻ ﯾﻌﻤﻞ دواء ELIGARD ﻋﻠﻰ زﯾﺎدة ﺗﻘﻠﯿﻞ ﻣﺴﺘﻮﯾﺎت اﻟﺘﺴﺘﻮﺳﺘﯿﺮون</p><p dir="RTL">ﻓﻲ اﻟﻤﺼﻞ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﺳﺘﺨﺪاﻣﮫ ﻛﻌﻼج وﺣﯿﺪ إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ أﻋﺮاض ﺗﺘﻌﻠﻖ ﺑﺎﻟﻀﻐﻂ اﻟﻮاﻗﻊ ﻋﻠﻰ اﻟﺤﺒﻞ اﻟﺸﻮﻛﻲ أو اﻹﺻﺎﺑﺔ ﺑﻮرمﻓﻲ اﻟﻌﻤﻮد اﻟﻔﻘﺮي.</p><p dir="RTL">وﻓﻲ ھﺬه اﻟﺤﺎﻟﺔ، ﻻ ﯾﻤﻜﻦ اﺳﺘﺨﺪام ELIGARD إﻻ ﺑﻤﺼﺎﺣﺒﺔ أدوﯾﺔ أﺧﺮى ﻟﻌﻼج ﺳﺮطﺎن اﻟﺒﺮوﺳﺘﺎﺗﺎ.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>اﻟﺘﺤﺬﯾﺮات ووﺳﺎﺋﻞ اﻟﻮﻗﺎﯾﺔ</strong></p><p dir="RTL">ﺗ<u>ﺤﺪث إﻟﻰ اﻟﻄﺒﯿﺐ، اﻟﺼﯿﺪﻟﻲ أو اﻟﻤﻤﺮﺿﺔ ﻗﺒﻞ اﺳﺘﻌﻤﺎل</u><u> ELIGARD</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; إذا ظﮭﺮت ﻟﺪﯾﻚ أي ﻣﻦ اﻟﺤﺎﻻت اﻟﺘﺎﻟﯿﺔ: أي ﻣﺸﺎﻛﻞﻓﻲ اﻟﻘﻠﺐ أو اﻷوﻋﯿﺔ اﻟﺪﻣﻮﯾﺔ، ﺑﻤﺎﻓﻲ ذﻟﻚ ﻣﺸﺎﻛﻞﻓﻲ ﻧﻈﻢ اﻟﻘﻠﺐ )اﺿﻄﺮاب ﻧﻈﻢ</p><p dir="RTL">اﻟﻘﻠﺐ(، أو إذا ﺗﻢ ﻋﻼج ﺣﺎﻟﺘﻚ ﺑﺎﻷدوﯾﺔ. ﻗﺪ ﯾﺰداد ﺧﻄﺮ اﻟﻤﺸﺎﻛﻞﻓﻲ ﻧﻈﻢ اﻟﻘﻠﺐ ﻋﻨﺪ اﺳﺘﻌﻤﺎل .ELIGARD</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﻛﻨﺖ<strong> ﺗﻌﺎﻧﻲ ﻣﻦ ﺻﻌﻮﺑﺎت ﻓﻲ اﻟﺘﺒﻮل</strong>.ﻓﯿﺠﺐ أن ﺗﺨﻀﻊ ﻟﻤﺮاﻗﺒﺔ ﺷﺪﯾﺪة ﺧﻼل اﻷﺳﺎﺑﯿﻊ اﻷوﻟﻰ ﻣﻦ اﻟﻌﻼج. &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا زاد<strong> اﻟﻀﻐﻂ اﻟﻮاﻗﻊ ﻋﻠﻰ اﻟﺤﺒﻞ اﻟﺸﻮﻛﻲ أو ﻛﺎﻧﺖ ھﻨﺎك ﺻﻌﻮﺑﺎت زاﺋﺪة ﻓﻲ اﻟﺘﺒﻮل</strong>. ﻓﯿﻤﺎ ﯾﺘﻌﻠﻖ ﺑﺄدوﯾﺔ أﺧﺮى ﻟﮭﺎ ﺗﺄﺛﯿﺮ ﺷﺒﯿﮫ ﺑﺘﺄﺛﯿﺮ دواء ELIGARD،&nbsp; ﺛﺒﺖ أن اﻟﺤﺎﻻت اﻟﺸﺪﯾﺪة ﻣﻦ آﺛﺎر اﻟﻀﻐﻂ اﻟﻮاﻗﻊ ﻋﻠﻰ اﻟﺤﺒﻞ اﻟﺸﻮﻛﻲ وﺗﻘﻠﺺ اﻟﺤﺎﻟﺒﯿﻦ ﺑﯿﻦ اﻟﻜﻠﯿﺘﯿﻦ واﻟﻤﺜﺎﻧﺔ</p><p dir="RTL">&nbsp;اﻟﺒﻮﻟﯿﺔ ﻗﺪ ﺗﺆدي إﻟﻰ ظﮭﻮر أﻋﺮاض ﺷﺒﯿﮭﺔ ﺑﺎﻟﺸﻠﻞ. وإذا زادت ھﺬه اﻟﻤﻀﺎﻋﻔﺎت، ﯾﺠﺐ اﻟﺒﺪء ﻓﻲ اﻟﻌﻼج اﻟﻤﺘﺒﻊ ﻗﯿﺎﺳﯿًﺎ. &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﺗﻌﺮﺿﺖ ﻟﺤﺎﻻت ﻣﻔﺎﺟﺌﺔ ﻣﻦ اﻟﺼﺪاع واﻟﻘﻲء وﺗﻐﯿﺮ اﻟﺤﺎﻟﺔ اﻟﺬھﻨﯿﺔ وأﺣﯿﺎﻧًﺎ ﺗﺪھﻮرﻓﻲ اﻟﻘﻠﺐ، ﺧﻼل أﺳﺒﻮﻋﯿﻦ ﻣﻦ اﺳﺘﺨﺪام دواء ELIGARD، ﻓﯿﺠﺐ إﺧﻄﺎر اﻟﻄﺒﯿﺐ أو ﻓﺮﯾﻖ اﻟﺮﻋﺎﯾﺔ اﻟﻄﺒﯿﺔ. وھﺬه ﺣﺎﻻت ﻧﺎدرة ﺗﺴﻤﻰ ﺑﺎﻟﺴﻜﺘﺔ اﻟﻨﺨﺎﻣﯿﺔ ﺗﻢ ﺛﺒﻮﺗﮭﺎ &quot;ﻓﻲ أدوﯾﺔ</p><p dir="RTL">أﺧﺮى&quot; ﻟﮭﺎ ﻧﻔﺲ ﺗﺄﺛﯿﺮ .ELIGARD</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﻛﻨﺖ ﺗﻌﺎﻧﻲ ﻣﻦ<strong> ﻣﺮض اﻟﺴﻜﺮي</strong> )ارﺗﻔﺎع ﻧﺴﺐ اﻟﺴﻜﺮﻓﻲ اﻟﺪم.( ﻓﯿﺠﺐ أن ﺗﺨﻀﻊ ﻟﻤﺮاﻗﺒﺔ ﻣﻨﺘﻈﻤﺔ ﺧﻼل ﻓﺘﺮة اﻟﻌﻼج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ﯾﻤﻜﻦ أن ﯾﺆدي اﻟﻌﻼج ﺑﺪواء ELIGARD إﻟﻰ زﯾﺎدة ﺧﻄﺮ اﻹﺻﺎﺑﺔ ﺑﺎﻟﻜﺴﻮر ﺑﺴﺒﺐ ھﺸﺎﺷﺔ اﻟﻌﻈﺎم )ﻧﻘﺺ ﻓﻲ ﻛﺜﺎﻓﺔ اﻟﻌﻈﺎم.(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وردت ﺗﻘﺎرﯾﺮ ﺣﻮل ﺣﺪوث ﺣﺎﻻت إﺻﺎﺑﺔ ﺑﺎﻻﻛﺘﺌﺎب ﺑﯿﻦ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﺘﻨﺎوﻟﻮن .Eligard إذا ﻛﻨﺖ ﺗﺘﻨﺎول ھﺬا اﻟﺪواء وﺗﻌﺎﻧﻲ ﻣﻦ</p><p dir="RTL">ﺷﻌﻮر ﺑﺎﻻﻛﺘﺌﺎب، ﻓﻌﻠﯿﻚ إﺧﺒﺎر طﺒﯿﺒﻚ.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وردت ﺗﻘﺎرﯾﺮ ﺣﻮل ﺣﺪوث ﺣﺎﻻت إﺻﺎﺑﺔ ﺑﺄﻣﺮاض ﻗﻠﺒﯿﺔ وﻋﺎﺋﯿﺔ ﺑﯿﻦ اﻟﻤﺮﺿﻰ اﻟﺬﯾﻦ ﯾﺘﻨﺎوﻟﻮن أدوﯾﺔ ﻣﻤﺎﺛﻠﺔ ﻟﺪواء Eligard وﻟﻜﻦ ﻟﻢ</p><p dir="RTL">ﯾُﻌﺮف ﺑﻌﺪ ﻣﺎ إذا ﻛﺎﻧﺖ ھﺬه اﻷﻣﺮاض ﻣﺘﻌﻠﻘﺔ ﺑﺘﻠﻚ اﻟﻤﻨﺘﺠﺎت أم ﻻ. إذا ﻛﻨﺖ ﺗﺘﻨﺎول ھﺬا اﻟﺪواء وأﺻﺒﺤﺖ ﺗﻌﺎﻧﻲ ﻣﻦ ﻋﻼﻣﺎت اﻹﺻﺎﺑﺔ ﺑﻤﺮضﻗﻠﺒﻲ</p><p dir="RTL">وﻋﺎﺋﻲ، ﻓﻌﻠﯿﻚ إﺧﺒﺎر طﺒﯿﺒﻚ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp; وردت ﺗﻘﺎرﯾﺮ ﺣﻮل ﺣﺪوث ﻧﻮﺑﺎت ﺗﺸﻨﺠﯿﺔ ﻟﺪى ﺑﻌﺾ اﻟﻤﺮﺿﻰ ﺑﻌﺪ إﻋﻄﺎﺋﮭﻢ .ELIGARD وإن ﻛﻨﺖ ﺗﺘﻨﺎول .ELIGARD</p><p dir="RTL">واﻧﺘﺎﺑﺘﻚ اﻟﻨﻮﺑﺎت اﻟﺘﺸﻨﺠﯿﺔ، ﻓﺄﺧﺒﺮ طﺒﯿﺒﻚ ﺑﺬﻟﻚ.</p><p>&nbsp;</p><p dir="RTL"><strong>ﻣﻀﺎﻋﻔﺎت ﻓﺘﺮة اﻟﻌﻼج اﻷوﻟﻰ</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﺧﻼل اﻷﺳﺒﻮع اﻷول ﻣﻦ اﻟﻌﻼج، ﯾﺤﺪث ﺑﺸﻜﻞ ﻋﺎم ارﺗﻔﺎع ﻗﺼﯿﺮ اﻷﻣﺪ ﻓﻲ ﻧﺴﺒﺔ ھﺮﻣﻮن اﻟﺬﻛﻮرة اﻟﺘﻨﺎﺳﻠﻲ اﻟﺘﺴﺘﻮﺳﺘﯿﺮونﻓﻲ اﻟﺪم. وﯾﻤﻜﻦ أن ﺗﺨﻒ ﯾﺆدي ھﺬا إﻟﻰ<strong> ﺗﺪھﻮر ﻣﺆﻗﺖ</strong> ﻓﻲ اﻷﻋﺮاض اﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻟﻤﺮض وﻛﺬﻟﻚ ظﮭﻮر أﻋﺮاض ﺟﺪﯾﺪة ﻟﻢ ﺗﺜﺒﺖ ﺣﺘﻰ ھﺬه اﻟﻠﺤﻈﺔ. وﺗﺘﻀﻤﻦ ھﺬه اﻷﻋﺮاض ﻋﻠﻰ وﺟﮫ اﻟﺨﺼﻮص ظﮭﻮر أﻟﻢ ﺑﺎﻟﻌﻈﺎم أو اﺿﻄﺮاﺑﺎت ﻓﻲ اﻟﺘﺒﻮل أو ﺿﻐﻂ ﻋﻠﻰ اﻟﺤﺒﻞ&nbsp; اﻟﺸﻮﻛﻲ أو إﻓﺮازات دﻣﻮﯾﺔﻓﻲ اﻟﺒﻮل. وﻋﺎدة ﻣﺎ</p><p dir="RTL">ﺣﺪة ھﺬه اﻷﻋﺮاض ﻣﻊ اﺳﺘﻤﺮار اﻟﻌﻼج. وإذا ﻟﻢ ﺗﺨﻒ ﺣﺪة اﻷﻋﺮاض،ﻓﯿﺠﺐ اﻻﺗﺼﺎل ﺑﺎﻟﻄﺒﯿﺐ.</p><p>&nbsp;</p><p dir="RTL"><strong>ﻓﻲ ﺣﺎﻟﺔ ﻋﺪم ﻓﻌﺎﻟﯿﺔ</strong><strong> ELIGARD</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﺳﺘﺘﻌﺮض ﻧﺴﺒﺔ ﻣﻦ اﻟﻤﺮﺿﻰ ﻟﻈﮭﻮر أورام ﻻ ﺗﻜﻮن ﺣﺴﺎﺳﺔ ﻻﻧﺨﻔﺎض ﻧﺴﺐ اﻟﺘﺴﺘﻮﺳﺘﯿﺮونﻓﻲ اﻟﻤﺼﻞ. ُﯾﺮﺟﻰ إﺧﻄﺎر اﻟﻄﺒﯿﺐ إذا ﻛﺎن ﻟﺪﯾﻚ</p><p dir="RTL">اﻧﻄﺒﺎع ﺑﺄن ﺗﺄﺛﯿﺮ&nbsp; ELIGARD ﺿﻌﯿﻒ ﺟﺪًا.</p><p>&nbsp;</p><p dir="RTL"><strong>أدوﯾﺔ أﺧﺮى ﺑﺎﻟﺪﻣﺞ ﻣﻊ</strong><strong> </strong><strong>ELIGARD</strong><strong> </strong>ﻗﺪ ﯾﺘﻔﺎﻋﻞ ELIGARD ﻣﻊ ﺑﻌﺾ اﻷدوﯾﺔ اﻟﻤﺴﺘﻌﻤﻠﺔ ﻟﻌﻼج ﻣﺸﺎﻛﻞ ﻧﻈﻢ اﻟﻘﻠﺐ )ﻣﺜﻞ ﻛﻮﯾﻨﯿﺪﯾﻦ، ﺑﺮوﻛﺎﯾﻨﻤﯿﺪ، أﻣﯿﻮدارون وﺳﻮﺗﺎﻟﻮل( أو أﻧﮫ ﻗﺪ ﯾﺰﯾﺪ ﻣﻦ ﺧﻄﺮ ﻣﺸﺎﻛﻞ ﻧﻈﻢ اﻟﻘﻠﺐ ﻋﻨﺪ اﺳﺘﻌﻤﺎﻟﮫ ﻣﻊ ﺑﻌﺾ اﻷدوﯾﺔ )ﻣﺜﻞ ﻣﯿﺜﺎدون، اﻟﻤﺴﺘﻌﻤﻞ ﻟﺘﺴﻜﯿﻦ اﻵﻻم وﻛﺠﺰء ﻣﻦ ﻋﻼج ﺗﻨﻘﯿﺔ اﻟﺪم ﻣﻦ اﻟﺴﻤﻮم</p><p dir="RTL">ﻓﻲ أﻋﻘﺎب إدﻣﺎن اﻟﻤﺨﺪرات(، ﻣﻮﻛﺴﯿﻔﻠﻮﻛﺴﺎﺳﯿﻦ )ﻣﻀﺎد ﺣﯿﻮي(، ﻣﻀﺎدات اﻟﺬھﺎن اﻟﻤﺴﺘﻌﻤﻠﺔ ﻟﻌﻼج اﻷﻣﺮاض اﻟﻨﻔﺴﯿﺔ اﻟﺸﺪﯾﺪة.</p><p>&nbsp;</p><p dir="RTL">أﺑﻠﻎ اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ إذا ﻛﻨﺖ ﺗﺘﻨﺎول أي أدوﯾﺔ أﺧﺮى أو ﺗﻜﻮن ﻗﺪ ﺗﻨﺎوﻟﺘﮭﺎ ﻣﺆﺧ&nbsp;ًﺮا، ﺑﻤﺎ ﻓﻲ ذﻟﻚ اﻷدوﯾﺔ اﻟﻤﺴﺘﺨﺪﻣﺔ دون وﺻﻔﺔ طﺒﯿﺔ.</p><p dir="RTL"><strong>اﻟﺤﻤﻞ واﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﯿﻌﯿﺔ</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">دواء ELIGARD ﻏﯿﺮ ﻣﺨﺼﺺ ﻟﻠﺴﯿﺪات.</p><p>&nbsp;</p><p dir="RTL"><strong>ﻗﯿﺎدة اﻟﺴﯿﺎرة واﺳﺘﺨﺪام اﻵﻻت</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﯾﻌﺪ اﻟﺸﻌﻮر ﺑﺎﻹﺟﮭﺎد واﻟﺪوﺧﺔ واﺿﻄﺮاﺑﺎت اﻟﺮؤﯾﺔ ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺤﺘﻤﻠﺔ ﻟﻠﻌﻼج ﺑﺪواء ELIGARD أو ﻗﺪ ﺗﻜﻮن ﻧﺎﺗﺠﺔ ﻋﻦ اﻟﻤﺮض. إذا</p><p>.اﻵﻻت ﺗﺸﻐﯿﻞ أو اﻟﺴﯿﺎرات ﻗﯿﺎدة ﻋﻨﺪ اﻟﺤﺬر َخ&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻓﺘﻮ اﻟﺠﺎﻧﺒﯿﺔ، اﻵﺛﺎر ھﺬه ﻣﻦ ﻋﺎﻧﯿﺖ</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اﻟﺠﺮﻋﺔ</strong></p><p>&nbsp;</p><p dir="RTL">اﺳﺘﻌﻤﻞ ھﺬا اﻟﺪواء داﺋ&nbsp; ًﻤﺎ وﻓﻖ إرﺷﺎدات اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ ﺑﺎﻟﻀﺒﻂ. اﺳﺘﺸﺮ اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ إذا ﻛﺎﻧﺖ ﻟﺪﯾﻚ ﺷﻜﻮك.</p><p dir="RTL">إذا ﻟﻢ ﯾﺼﻒ اﻟﻄﺒﯿﺐ ﻏﯿﺮ ذﻟﻚ، ﻓﯿﺠﺐ ﺗﻨﺎول دواء ELIGARD 22.5 ﻣﻠﯿﻐﺮام<strong> ﻣﺮة ﻛﻞ ﺛﻼﺛﺔ أﺷﮭﺮ</strong>.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﯾﻤﺜﻞ اﻟﻤﺤﻠﻮل اﻟﺬي ﯾﺘﻢ ﺣﻘﻨﮫ ﻣﺨﺰوﻧًﺎ ﻣﻦ اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ﯾﺘﻢ ﻣﻨﮫ إﻓﺮاز اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ أﺳﯿﺘﺎت اﻟﻠﯿﻮﺑﺮورﻟﯿﻦ ﺑﺎﺳﺘﻤﺮار ﻋﻠﻰ ﻣﺪار ﻓﺘﺮة ﺗﺒﻠﻎ ﺛﻼﺛﺔ</p><p dir="RTL">أﺷﮭﺮ.</p><p>&nbsp;</p><p dir="RTL"><strong>اﺧﺘﺒﺎرات إﺿﺎﻓﯿﺔ</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﯾﺠﺐ اﻟﺘﺤﻘﻖ ﻣﻦ اﻻﺳﺘﺠﺎﺑﺔ ﻟﻠﻌﻼج ﺑﺪواء&nbsp;ELIGARD&nbsp;ﺑﻮاﺳﻄﺔ اﻟﻄﺒﯿﺐ ﻣﻦ ﺧﻼلﻓﺤﺺ&nbsp;ِﻗﯿﻢ إﻛﻠﯿﻨﯿﻜﯿﺔ ﻣﻌﯿﻨﺔ وﻗﯿﺎس ﻧﺴﺐ ﻣﺎ ﯾﺴﻤﻰ ﺑﻤﻮﻟﺪ</p><p dir="RTL">اﻟﻤﻀﺎدات اﻟﺨﺎص ﺑﺎﻟﺒﺮوﺳﺘﺎﺗﺎ (PSA)ﻓﻲ اﻟﺪم.</p><p dir="RTL"><strong>طﺮﯾﻘﺔ اﻻﺳﺘﻌﻤﺎل</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﯾﺠﺐ اﺳﺘﻌﻤﺎل ELIGARD ﺑﻮاﺳﻄﺔ اﻟﻄﺒﯿﺐ أو اﻟﻤﻤﺮﺿﺔ ﻓﻘﻂ. وﯾﺠﺐ ﻋﻠﯿﮭﻢ أﯾﻀًﺎ ﻣﺮاﻋﺎة ﺗﺤﻀﯿﺮ اﻟﻤﺤﻠﻮل اﻟﺠﺎھﺰ ﻟﻼﺳﺘﻌﻤﺎل )وﻓﻘًﺎ</p><p dir="RTL">ﻟﻺرﺷﺎدات اﻟﻤﻮﺿﺤﺔﻓﻲ اﻟﺠﺰء رﻗﻢ<em> 7</em> ﺑﻌﻨﻮان &quot;ﻣﻌﻠﻮﻣﺎت ﻷﺧﺼﺎﺋﻲ اﻟﺮﻋﺎﯾﺔ اﻟﺼﺤﯿﺔ&quot;،ﻓﻲ ﻧﮭﺎﯾﺔ ھﺬه اﻟﻨﺸﺮة.(</p><p>&nbsp;</p><p dir="RTL">ﺑﻌﺪ اﻟﺘﺤﻀﯿﺮ، ﯾﺠﺐ اﺳﺘﻌﻤﺎل ELIGARD ﺑﺎﻟﺤﻘﻦ ﺗﺤﺖ اﻟﺠﻠﺪ )اﻟﺤﻘﻦﻓﻲ اﻟﻨﺴﯿﺞ اﻟﻤﻮﺟﻮد ﺗﺤﺖ ﺳﻄﺢ اﻟﺠﻠﺪ.( وﯾﺤﻈﺮ ﺑﺸﺪة اﻟﻘﯿﺎم ﺑﺎﻟﺤﻘﻦﻓﻲ</p><p dir="RTL">اﻟﺸﺮﯾﺎن أو اﻟﻮرﯾﺪ.ﻓﻲ ﺣﺎﻟﺔ ﺣﻘﻦ ﻣﻮاد ﻓﻌﺎﻟﺔ أﺧﺮى ﺗﺤﺖ اﻟﺠﻠﺪ، ﯾﺠﺐ ﺗﻐﯿﯿﺮ ﻣﻮﺿﻊ اﻟﺤﻘﻦ ﺑﺼﻔﺔ دورﯾﺔ.</p><p>&nbsp;</p><p dir="RTL"><strong>ﻓﻲ ﺣﺎﻟﺔ اﺳﺘﻌﻤﺎل ﺟﺮﻋﺔ زاﺋﺪةﻣﻦ</strong><strong> ELIGARD</strong></p><p dir="RTL">&nbsp;ِﻗﺒﻞ&nbsp;ﻧﻈ&nbsp;ًﺮا&nbsp;ﻷن اﻟﺤﻘﻦ ﯾﺠﺐ أن ﯾﻜﻮن ﻋﺎدة ﺑﻮاﺳﻄﺔ اﻟﻄﺒﯿﺐ أو ﻣﺘﺨﺼﺺ ذي ﺗﺪرﯾﺐ ﻣﻼﺋﻢ، ﻓﻼ ﯾﺘﻮﻗﻊ ﺗﻨﺎول ﺟﺮﻋﺔ زاﺋﺪة.&nbsp;إﻻ أﻧﮫﻓﻲ ﺣﺎﻟﺔ اﺳﺘﻌﻤﺎل ﻛﻤﯿﺔ زاﺋﺪة ﻋﻦ اﻟﺘﻲ ﺗﻢ ﺗﺤﺪﯾﺪھﺎ، ﯾﺠﺐ اﻟﺨﻀﻮع ﻟﻤﺮاﻗﺒﺔ ﺧﺎﺻﺔ واﻟﺤﺼﻮل ﻋﻠﻰ ﻋﻼج إﺿﺎﻓﻲ وﻓﻘًﺎ&nbsp;ﻟﻠﺤﺎﺟﺔ ﻣﻦ</p><p dir="RTL">اﻟﻄﺒﯿﺐ.</p><p>&nbsp;</p><p dir="RTL"><strong>ﻓﻲ ﺣﺎﻟﺔ ﻧﺴﯿﺎن ﺗﻨﺎول</strong><strong> ELIGARD</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﯾُﺮﺟﻰ إﺧﻄﺎر اﻟﻄﺒﯿﺐ إذا ﻛﻨﺖ ﺗﻈﻦ أﻧﻚ ﻧﺴﯿﺖ ﺗﻨﺎول اﻟﺠﺮﻋﺔ اﻟﻤﻘﺮرة ﻛﻞ ﺛﻼﺛﺔ أﺷﮭﺮ ﻣﻦ .ELIGARD</p><p>&nbsp;</p><p dir="RTL"><strong>آﺛﺎر اﻟﺘﻮﻗﻒ ﻋﻦ اﺳﺘﻌﻤﺎل</strong><strong> ELIGARD</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﻛﻘﺎﻋﺪة ﻋﺎﻣﺔ، ﯾﺘﻄﻠﺐ ﻋﻼج ﺳﺮطﺎن اﻟﺒﺮوﺳﺘﺎﺗﺎ ﺑﺪواء ELIGARD اﺳﺘﻌﻤﺎل اﻟﺪواء ﻋﻠﻰ اﻟﻤﺪى اﻟﻄﻮﯾﻞ. وﻣﻦ ﺛ ّﻢ،ﻓﻼ ﯾﺠﺐ اﻟﺘﻮﻗﻒ ﻋﻦ اﻟﻌﻼج</p><p dir="RTL">ﺣﺘﻰ وإن ظﮭﺮ ﺗﺤﺴﻦﻓﻲ اﻷﻋﺮاض أو أﻧﮭﺎ اﺧﺘﻔﺖ ﺗﻤﺎ&nbsp;ًﻣﺎ.</p><p dir="RTL">وإذا ﺗﻢ إﯾﻘﺎف اﻟﻌﻼج ﺑﺪواء ELIGARD ﻗﺒﻞ اﻟﻮﻗﺖ اﻟﻤﻨﺎﺳﺐ، ﻓﯿﻤﻜﻦ أن ﯾﺤﺪث ﺗﺪھﻮرﻓﻲ اﻷﻋﺮاض اﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻟﻤﺮض.</p><p dir="RTL"><strong>ﻻ ﯾﺠﺐ إﯾﻘﺎف اﻟﻌﻼج ﻗﺒﻞ اﻟﻮﻗﺖ اﻟﻤﻨﺎﺳﺐدون اﺳﺘﺸﺎرة اﻟﻄﺒﯿﺐ ﻣﺴﺒﻘًﺎ.</strong></p><p dir="RTL"><strong>وإذا ﻛﺎن ﻟﺪﯾﻚ أي اﺳﺘﻔﺴﺎر آﺧﺮ ﺣﻮل اﺳﺘﺨﺪام ھﺬا اﻟﺪواء، ﻓﺎﺳﺄل اﻟﻄﺒﯿﺐ، اﻟﺼﯿﺪﻟﻲ أو اﻟﻤﻤﺮﺿﺔ.</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL">ﻛﻤﺎ ھﻮ اﻟﺤﺎل ﻣﻊ ﺟﻤﯿﻊ اﻷدوﯾﺔ، ﻣﻦ اﻟﻤﻤﻜﻦ أن ﯾﺘﺴﺒﺐ ELIGARD ﻓﻲ ظﮭﻮر آﺛﺎر ﺟﺎﻧﺒﯿﺔ وﻟﻜﻨﮭﺎ ﻻ ﺗﺤﺪث ﻟﺠﻤﯿﻊ اﻷﺷﺨﺎص.</p><p>&nbsp;</p><p dir="RTL">ﻣﻦ ﺗﻜﻮن اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺘﻲ ﺗﻤﺖ ﻣﻼﺣﻈﺘﮭﺎ أﺛﻨﺎء اﻟﻌﻼج ﺑﺪواء ELIGARD ﻧﺎﺗﺠﺔﻓﻲ اﻷﺳﺎس ﻋﻦ اﻷﺛﺮ اﻟﺨﺎص ﻟﻤﺎدة أﺳﯿﺘﺎت اﻟﻠﯿﻮﺑﺮورﻟﯿﻦ اﻟﻔﻌﺎﻟﺔ، وﺑﺎﻟﺘﺤﺪﯾﺪ زﯾﺎدة واﻧﺨﻔﺎض ﻧﺴﺒﺔ ھﺮﻣﻮﻧﺎت ﻣﻌﯿﻨﺔ. وﺗﺘﻤﺜﻞ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺜﺒﺘﺔ اﻷﻛﺜﺮ ﺷﯿﻮﻋًﺎ ﻓﻲ ﻧﻮﺑﺎت ارﺗﻔﺎع ﻓﻲ اﻟﺤﺮارة )ﻓﻲ 58 %</p><p dir="RTL">اﻟﻤﺮﺿﻰ ﺗﻘﺮﯾﺒﺎ( واﻟﺸﻌﻮر ﺑﺎﻟﻐﺜﯿﺎن ووﻋﻜﺔ ﺻﺤﯿﺔ واﻹﺟﮭﺎد، ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ﺗﮭﯿﺠﺎت ﻣﻮﺿﻌﯿﺔ ﻣﺆﻗﺘﺔﻓﻲ ﻣﻜﺎن اﻟﺤﻘﻦ.</p><p>&nbsp;</p><p dir="RTL"><strong>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻷوﻟﯿﺔ</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">)وھﻮ ﺧﻼل اﻷﺳﺎﺑﯿﻊ اﻷوﻟﻰ ﻣﻦ اﻟﻌﻼج ﺑﺪواء ELIGARD، ﻗﺪ ﺗﺘﺪھﻮر اﻷﻋﺮاض اﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻟﻤﺮض، وذﻟﻚ ﻷﻧﮫﻓﻲ اﻟﺤﺎﻟﺔ اﻷوﻟﻰ ﯾﺤﺪث ﺑﺸﻜﻞ ﻋﺎم ﻗﺒﻞ ارﺗﻔﺎع ﻗﺼﯿﺮ اﻷﻣﺪ ﻓﻲ ﻧﺴﺒﺔ ھﺮﻣﻮن اﻟﺬﻛﻮرة اﻟﺘﻨﺎﺳﻠﻲ اﻟﺘﺴﺘﻮﺳﺘﯿﺮونﻓﻲ اﻟﺪم. وﻣﻦ ﺛ ّﻢ، ﻓﻘﺪ ﯾﺼﻒ اﻟﻄﺒﯿﺐ اﺳﺘﻌﻤﺎل ﻣﻀﺎد ﻣﻨﺎﺳﺐ ﻟﻸﻧﺪروﺟﯿﻦ ﻣﺎدة ﺗﻌﻤﻞ ﻋﻠﻰ ﻣﻨﻊ ﺗﺄﺛﯿﺮ اﻟﺘﺴﺘﻮﺳﺘﯿﺮون(ﻓﻲ اﻟﻤﺮﺣﻠﺔ اﻷوﻟﻰ ﻣﻦ اﻟﻌﻼج ﻟﺘﻘﻠﯿﻞ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺤﺘﻤﻠﺔ )اﻧﻈﺮ أﯾﻀًﺎ اﻟﺠﺰء رﻗﻢ<em> </em><em>2</em> ﺑﻌﻨﻮان</p><p dir="RTL">اﺳﺘﺨﺪام<em> ELIGARD</em>، ﻣﻀﺎﻋﻔﺎتﻓﺘﺮة اﻟﻌﻼج اﻷوﻟﻰ.(</p><p dir="RTL"><strong>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﻮﺿﻌﯿﺔ</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﺗﻌﺪ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﻮﺿﻌﯿﺔ اﻟﻤﺜﺒﺖ ظﮭﻮرھﺎ ﺑﻌﺪ ﺣﻘﻦ ELIGARD ھﻲ ﻋﺎدة ﺗﻠﻚ اﻟﺘﻲ ﺗﻈﮭﺮ ﻏﺎﻟ ًﺒﺎ ﻣﻊ اﻟﻤﺴﺘﺤﻀﺮات اﻟﻤﻤﺎﺛﻠﺔ اﻟﻤﺤﻘﻮﻧﺔ</p><p dir="RTL">ﺗﺤﺖ اﻟﺠﻠﺪ )اﻟﻤﺴﺘﺤﻀﺮات اﻟﺘﻲ ﯾﺘﻢ ﺣﻘﻨﮭﺎ ﻓﻲ اﻟﻨﺴﯿﺞ اﻟﻤﻮﺟﻮد ﺗﺤﺖ ﺳﻄﺢ اﻟﺠﻠﺪ.( وﯾﺤﺪث ﺣﺮﻗﺎن ﺧﻔﯿﻒ ﺑﻌﺪ اﻟﺤﻘﻦ ﻣﺒﺎﺷﺮة ﺑﺸﻜﻞ ﺷﺎﺋﻊ ﺟﺪًا.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">وﻣﻦ اﻵﺛﺎر اﻟﺸﺎﺋﻌﺔ أﯾﻀﺎ اﻟﺸﻌﻮر ﺑﻮﺧﺰ أو أﻟﻢ ﺑﻌﺪ اﻟﺤﻘﻦ، ﺑﺎﻹﺿﺎﻓﺔ إﻟﻰ ظﮭﻮر ﻛﺪﻣﺔﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ. ﻛﻤﺎ ﺛﺒﺖ ﺷﯿﻮع اﺣﻤﺮار اﻟﺠﻠﺪﻓﻲ ﻣﻮﺿﻊ</p><p dir="RTL">اﻟﺤﻘﻦ. إﻻ أن ﺗﺼﻠﺐ اﻷﻧﺴﺠﺔ وﺗﻘﺮﺣﺎت اﻟﺠﻠﺪ ﻏﯿﺮ ﺷﺎﺋﻌﯿﻦ.</p><p>&nbsp;</p><p dir="RTL">ﺗﻜﻮن&nbsp;ھﺬه&nbsp;اﻵﺛﺎر&nbsp;اﻟﺠﺎﻧﺒﯿﺔ&nbsp;اﻟﻤﻮﺿﻌﯿﺔ&nbsp;اﻟﺘﺎﻟﯿﺔ&nbsp;ﻟﻠﺤﻘﻦ&nbsp;ﺗﺤﺖ&nbsp;اﻟﺠﻠﺪ&nbsp;ﻏﯿﺮ&nbsp;ﺣﺎدة&nbsp;وﺛﺒﺖ&nbsp;أﻧﮭﺎ&nbsp;ﻗﺼﯿﺮة&nbsp;اﻷﻣﺪ.&nbsp;ﻛﻤﺎ&nbsp;أﻧﮭﺎ&nbsp;ﻻ&nbsp;ﺗﻈﮭﺮ&nbsp;ﻣﺮة&nbsp;أﺧﺮى&nbsp;ﻓﯿﻤﺎ&nbsp;ﺑﯿﻦ&nbsp;اﻟ&nbsp;&nbsp;ُﺤﻘﻦ</p><p dir="RTL">اﻟﻔﺮدﯾﺔ.</p><p>&nbsp;</p><p dir="RTL"><strong>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻷﻛﺜﺮ ﺷﯿﻮﻋًﺎ )ﻗﺪ ﺗﻈﮭﺮ ﻓﻲ أﻛﺜﺮﻣﻦ ﺷﺨﺺ واﺣﺪ ﻣﻦ ﻛﻞ</strong><strong> 10</strong><strong> أﺷﺨﺎص</strong><strong>(</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﺎ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﻮﺿﻌﯿﺔ أﻋﻼه(</p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ﻧﻮﺑﺎت ارﺗﻔﺎع ﻓﻲ اﻟﺤﺮارة&nbsp; -&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻧﺰﯾﻒ ﺗﻠﻘﺎﺋﻲ ﻓﻲ اﻟﺠﻠﺪ أو اﻟﻐﺸﺎء اﻟﻤﺨﺎطﻲ واﺣﻤﺮار اﻟﺠﻠﺪ - &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;اﻹﺣﺴﺎس ﺑﺎﻹﺟﮭﺎد واﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺘﻌﻠﻘﺔ ﺑﺎﻟﺤﻘﻦ )اﻧﻈﺮ أﯾ</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﺸﺎﺋﻌﺔ )ﻗﺪ ﺗﻈﮭﺮ ﻓﻲ ﺷﺨﺺ واﺣﺪ ﻛﺤﺪ أﻗﺼﻰﻣﻦ ﻛﻞ</strong><strong> 10</strong><strong> أﺷﺨﺎص(</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺘﮭﺎب اﻷﻧﻒ واﻟﺤﻠﻖ )أﻋﺮاض ﻧﺰﻟﺔ اﻟﺒﺮد اﻟﻌﺎدﯾﺔ(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺸﻌﻮر ﺑﺎﻟﻐﺜﯿﺎن ووﻋﻜﺔ ﺻﺤﯿﺔ وإﺳﮭﺎل واﻟﺘﮭﺎب اﻟﻤﻌﺪة واﻷﻣﻌﺎء )اﻻﻟﺘﮭﺎب اﻟﻤﻌﺪي اﻟﻤﻌﻮي/اﻟﺘﮭﺎب اﻟﻘﻮﻟﻮن(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺸﻌﻮر ﺑﺤﻜﺔ واﻟﺘﻌﺮق اﻟﻠﯿﻠﻲ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أﻟﻢ ﻓﻲ اﻟﻤﻔﺎﺻﻞ &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺬھﺎب إﻟﻰ اﻟﺤﻤﺎم ﺑﺼﻮرة ﻏﯿﺮ ﻋﺎدﯾﺔ ﻟﻠﺘﺒﻮل )ﺣﺘﻰ أﺛﻨﺎء اﻟﻠﯿﻞ( وﺻﻌﻮﺑﺔ ﻋﻨﺪ ﺑﺪء اﻟﺘﺒﻮل وآﻻم أﺛﻨﺎء اﻟﺘﺒﻮل وﻗﻠﺔ ﻛﻤﯿﺔ اﻟﺒﻮل &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أﻟﻢ وﺗﻮرمﻓﻲ ﻣﻨﻄﻘﺔ اﻟﺼﺪر واﻧﻜﻤﺎش وآﻻمﻓﻲ اﻟﺨﺼﯿﺘﯿﻦ وﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻹﻧﺠﺎب )اﻟﻌﻘﻢ( وﺧﻠﻞﻓﻲ وظﯿﻔﺔ اﻻﻧﺘﺼﺎب وﺗﻘﻠﺺ</p><p dir="RTL">ﺣﺠﻢ اﻟﻘﻀﯿﺐ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رﺟﻔﺎت )ﻧﻮﺑﺎت ﻗﺸﻌﺮﯾﺮة ﻣﻔﺮطﺔ ﺗﺼﺤﺒﮭﺎ أﻋﺮاض ﺣﻤﻰ ﺷﺪﯾﺪة( وﺣﺎﻟﺔ ﻣﻦ اﻟﻀﻌﻒ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻧﺰﯾﻒ ﻟﻔﺘﺮات طﻮﯾﻠﺔ وﺗﻐﯿﺮاتﻓﻲ ﻗﯿﻢ اﻟﺪم واﻧﺨﻔﺎض ﻋﺪد ﺧﻼﯾﺎ اﻟﺪم اﻟﺤﻤﺮاء/ﺗﺪﻧﻲ ﺗﻌﺪاد ﺧﻼﯾﺎ اﻟﺪم اﻟﺤﻤﺮاء</p><p>&nbsp;</p><p dir="RTL"><strong>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ ﻏﯿﺮ اﻟﺸﺎﺋﻌﺔ )ﻗﺪ ﺗﻈﮭﺮ ﻓﻲ ﺷﺨﺺ واﺣﺪ ﻛﺤﺪ أﻗﺼﻰﻣﻦ ﻛﻞ</strong><strong> 100</strong><strong> ﺷﺨﺺ(</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺘﮭﺎب اﻟﻤﺴﺎﻟﻚ اﻟﺒﻮﻟﯿﺔ واﻟﺘﮭﺎب ﻣﻮﺿﻌﻲ ﺑﺎﻟﺠﻠﺪ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻣﻀﺎﻋﻔﺎت ﻣﺮض اﻟﺴﻜﺮي اﻟﺘﺬوق واﻟﺸﻢ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&middot;&nbsp;&nbsp;&nbsp; أﺣﻼم ﻏﯿﺮ ﻋﺎدﯾﺔ واﻟﺸﻌﻮر ﺑﺎﻻﻛﺘﺌﺎب وﻗﻠﺔ اﻟﺸﮭﻮة اﻟﺠﻨﺴﯿﺔ &middot;&nbsp;&nbsp; اﻟﺸﻌﻮر ﺑﺪوﺧﺔ &nbsp;وﺻﺪاع وﺗﻐﯿﺮ اﻹﺣﺴﺎسﻓﻲ اﻟﺠﻠﺪ وأرق واﺿﻄﺮابﻓﻲ ﺣﺎﺳﺘﻲ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارﺗﻔﺎع ﺿﻐﻂ اﻟﺪم واﻧﺨﻔﺎض ﺿﻐﻂ اﻟﺪم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺿﯿﻖﻓﻲ اﻟﺘﻨﻔﺲ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إﻣﺴﺎك وﺟﻔﺎف اﻟﻔﻢ وﻋﺴﺮ اﻟﮭﻀﻢ )اﺿﻄﺮابﻓﻲ اﻟﮭﻀﻢ ﻣﻊ أﻋﺮاض ﺗﺸﺒﮫ ﺣﺎﻟﺔ اﻣﺘﻼء اﻟﻤﻌﺪة وأﻟﻢﻓﻲ اﻟﻤﻌﺪة وﺗﺠﺸﺆ وﻏﺜﯿﺎن وﻗﻲء</p><p dir="RTL">واﻟﺸﻌﻮر ﺑﺤﺮﻗﺔﻓﻲ اﻟﻤﻌﺪة( وﻗﻲء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻨﺪي اﻟﺠﻠﺪ وﺗﻌﺮق زاﺋﺪ &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أﻟﻢ ﺑﺎﻟﻈﮭﺮ وﺗﺸﻨﺞ اﻟﻌﻀﻼت &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺒﻮل اﻟﺪﻣﻮي )ظﮭﻮر دمﻓﻲ اﻟﺒﻮل(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻘﻠﺺ ﻋﻀﻠﺔ اﻟﻤﺜﺎﻧﺔ واﻟﺬھﺎب ﻟﺪورة اﻟﻤﯿﺎه ﻟﻠﺘﺒﻮل ﺑﺸﻜﻞ أﻛﺜﺮ ﻣﻦ اﻟﻤﻌﺘﺎد وﻋﺪم اﻟﻘﺪرة ﻋﻠﻰ اﻟﺘﺒﻮل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻀﺨﻢ ﻧﺴﯿﺞ اﻟﺼﺪر ﻋﻨﺪ اﻟﺮﺟﺎل واﻟﻌﺠﺰ اﻟﺠﻨﺴﻲ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺸﻌﻮر ﺑﻨﻌﺎس )اﻟﻨﻮم( وأﻟﻢ وﺣﻤﻰ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زﯾﺎدة اﻟﻮزن طﻮﯾﻠﺔ&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻓﻘﺪان اﻟﺘﻮازن واﻟﺸﻌﻮر ﺑﺎﻟﺪوار اﻟﺨﻔﯿﻒ &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺿﻤﻮر اﻟﻌﻀﻼت/ﻓﻘﺪان أﻧﺴﺠﺔ اﻟﻌﻀﻼت ﺑﻌﺪ اﻻﺳﺘﻌﻤﺎل ﻋﻠﻰ ﻣﺪار ﻓﺘﺮة</p><p>&nbsp;</p><p dir="RTL"><strong>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻨﺎدرة )ﻗﺪ ﺗﻈﮭﺮ ﻓﻲ ﺷﺨﺺ واﺣﺪ ﻛﺤﺪ أﻗﺼﻰﻣﻦ ﻛﻞ 1000 ﺷﺨﺺ(</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot; ﺣﺮﻛﺎت ﻻ إرادﯾﺔ ﻏﯿﺮ طﺒﯿﻌﯿﺔ &middot;&nbsp; ﻓﻘﺪان ﻣﻔﺎﺟﺊ ﻟﻠﻮﻋﻲ )اﻹﻏﻤﺎء( &middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻧﺘﻔﺎخ اﻟﺒﻄﻦ ﺑﺎﻟﻐﺎزات واﻟﺘﺠﺸﺆ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﺴﺎﻗﻂ اﻟﺸﻌﺮ وطﻔﺢ ﺟﻠﺪي )ﺑﺜﻮر ﻋﻠﻰ ﺳﻄﺢ اﻟﺠﻠﺪ(</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻘﺮح ﻣﻜﺎن اﻟﺤﻘﻦ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أﻟﻢ ﻓﻲ اﻟﺼﺪر</p><p>&nbsp;</p><p dir="RTL"><strong>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻨﺎدرة ﺟﺪًا</strong><strong> )ﻗﺪ ﺗﻈﮭﺮ ﻓﻲ ﺷﺨﺺ واﺣﺪ ﻛﺤﺪ أﻗﺼﻰ ﻣﻦ ﻛﻞ 10000 ﺷﺨﺺ(</strong></p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﺘﻨﻜﺮز )ﻣﻮت ﻣﻮﺿﻌﻲ ﻟﻸﻧﺴﺠﺔ(ﻓﻲ ﻣﻮﺿﻊ اﻟﺤﻘﻦ</p><p>&nbsp;</p><p dir="RTL"><strong>ﻏﯿﺮ اﻟﻤﻌﺮوﻓﺔ )ﯾﺘﻌﺬر ﺗﻘﺪﯾﺮ ﻣﺪى ﺷﯿﻮﻋﮭﺎ ﺑﺎﻻﻋﺘﻤﺎد ﻋﻠﻰ اﻟﻤﻌﻄﯿﺎت اﻟﻤﺘﺎﺣﺔ(</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻐﯿﺮات ﻓﻲ ﻣﺨﻄﻂ ﻛﮭﺮﺑﯿﺔ اﻟﻘﻠﺐ أ.ك.ج. )إطﺎﻟﺔ (QT</p><p>&nbsp;</p><p dir="RTL"><strong>اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻷﺧﺮى</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻷﺧﺮى اﻟﻤﺬﻛﻮرةﻓﻲ اﻟﻤﺮاﺟﻊ اﻟﺘﻲ ﺗﺘﻌﻠﻖ ﺑﺎﻟﻌﻼج ﺑﺎﻟﻠﯿﻮﺑﺮورﻟﯿﻦ، وھﻮ اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔﻓﻲ ELIGARD، ھﻲ اﻹﺻﺎﺑﺔ ﺑﻮذﻣﺔ )ﺗﺮاﻛﻢ اﻟﺴﻮاﺋﻞﻓﻲ اﻷﻧﺴﺠﺔ وﺗﺒﺪو ﻛﺘﻮرمﻓﻲ اﻟﯿﺪﯾﻦ واﻟﻘﺪﻣﯿﻦ( واﻧﺼﻤﺎم رﺋﻮي )ﯾﺆدي إﻟﻰ ظﮭﻮر أﻋﺮاض ﻣﺜﻞ ﺿﯿﻖ وﺻﻌﻮﺑﺔﻓﻲ اﻟﺘﻨﻔﺲ وأﻟﻢﻓﻲ اﻟﺼﺪر( وﺧﻔﻘﺎن اﻟﻘﻠﺐ )اﻟﺸﻌﻮر ﺑﻀﺮﺑﺎتﻗﻮﯾﺔ ﻓﻲ اﻟﻘﻠﺐ( وﺿﻌﻒﻓﻲ اﻟﻌﻀﻼت وﻧﻮﺑﺎتﻗﺸﻌﺮﯾﺮة وطﻔﺢ ﺟﻠﺪي وﺿﻌﻒ اﻟﺬاﻛﺮة وﺿﻌﻒ اﻹﺑﺼﺎر. ﻗﺪ ﯾﻜﻮن ظﮭﻮر&nbsp;ﻋﻼﻣﺎت&nbsp;ﻣﺘﺰاﯾﺪة&nbsp;ﻋﻠﻰ&nbsp;ﺿﻤﻮرﻓﻲ&nbsp;ﻧﺴﯿﺞ&nbsp;اﻟﻌﻈﺎم&nbsp;)ھﺸﺎﺷﺔ&nbsp;اﻟﻌﻈﺎم(&nbsp;أﻣ&nbsp;ًﺮا&nbsp;ﻣﺘﻮﻗ&nbsp;&nbsp;ًﻌﺎ&nbsp;ﺑﻌﺪ&nbsp;اﻟﻌﻼج&nbsp;طﻮﯾﻞ&nbsp;اﻟﻤﺪى&nbsp;ﺑﺪواء&nbsp;.ELIGARD&nbsp;وﺑﺴﺒﺐ&nbsp;اﻹﺻﺎﺑﺔ</p><p dir="RTL">ﺑﮭﺸﺎﺷﺔ اﻟﻌﻈﺎم، ﯾﺰداد ﺧﻄﺮ اﻟﺘﻌﺮض ﻟﻜﺴﻮر.</p><p>&nbsp;</p><p dir="RTL">ﻗﺪ ﺗﻢ اﻹﺧﺒﺎرﻓﻲ أﺣﯿﺎن ﻧﺎدرة ﺑﺤﺪوث ردود ﻓﻌﻞ ﺗﺤﺴﺴﯿﺔ ﺧﻄﯿﺮة، اﻟﺤﺎﻟﺔ اﻟﺘﻲ ﺗﺴﺒﺐ ﺻﻌﻮﺑﺔﻓﻲ اﻟﺘﻨﻔﺲ أو اﻟﺪوار، وذﻟﻚ ﺑﻌﺪ إﻋﻄﺎء اﻟﻤﻨﺘﺠﺎت ﻣﻦ</p><p dir="RTL">ﻧﻔﺲ اﻟﻔﺼﯿﻠﺔ اﻟﺪواﺋﯿﺔ اﻟﺘﻲ ﯾﻨﺘﻤﻲ إﻟﯿﮭﺎ .ELIGARD</p><p dir="RTL">وﻗﺪ ﺗﻢ اﻹﺧﺒﺎر ﺑﺤﺪوث اﻟﻨﻮﺑﺎت اﻟﺘﺸﻨﺠﯿﺔ ﺑﻌﺪ إﻋﻄﺎء اﻟﻤﻨﺘﺠﺎت ﻣﻦ ﻧﻔﺲ اﻟﻔﺼﯿﻠﺔ اﻟﺪواﺋﯿﺔ اﻟﺘﻲ ﯾﻨﺘﻤﻲ إﻟﯿﮭﺎ .ELIGARD</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL"><strong>اﻹﺧﻄﺎر ﺑﺎﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ إذا ظﮭﺮ ﻟﺪﯾﻚ أي أﺛﺮ ﺟﺎﻧﺒﻲ ﻓﺘﺤﺪث إﻟﻰ اﻟﻄﺒﯿﺐ، اﻟﺼﯿﺪﻟﻲ أو اﻟﻤﻤﺮﺿﺔ. ﯾﻨﻄﺒﻖ ھﺬا اﻹرﺷﺎد ﻋﻠﻰ أي آﺛﺎر ﺟﺎﻧﺒﯿﺔ ﻣﺤﺘﻤﻠﺔ ﻻ ﺗُﺬﻛﺮ ﻓﻲ ھﺬه</strong></p><p dir="RTL"><strong>اﻟﻨﺸﺮة. ﯾﺘﯿﺢ اﻹﺧﻄﺎر ﺑﺎﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ اﻟﻤﺴﺎھﻤﺔ ﻓﻲ ﺗﻮﺳﯿﻊ اﻟﻤﻌﻠﻮﻣﺎت ﻋﻦ أﻣﺎن وﺳﻼﻣﺔ ھﺬا اﻟﺪواء.</strong></p><p dir="RTL"><strong>إذا ﺑﻠﻎ أي ﻣﻦ اﻵﺛﺎر اﻟﺠﺎﻧﺒﯿﺔ ﺣﺪ اﻟﺨﻄﻮرة أو إذا ﻻﺣﻈﺖ أي آﺛﺎر ﺟﺎﻧﺒﯿﺔ ﻏﯿﺮ اﻟﻤﻮﺿﺤﺔ ﻓﻲ ھﺬه اﻟﻨﺸﺮة، ﻓ</strong><strong>&nbsp;ُﯿﺮﺟﻰ إﺧﻄﺎر اﻟﻄﺒﯿﺐ أو اﻟﺼﯿﺪﻟﻲ.</strong></p><p><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p dir="RTL">ﯾﺤﻔﻆ ﺑﻌﯿﺪًا ﻋﻦ ﻣﺠﺎل رؤﯾﺔ اﻷطﻔﺎل وﻣﺘﻨﺎول أﯾﺪﯾﮭﻢ.</p><p>&nbsp;</p><p dir="RTL">ﻻ ﯾﺠﺐ اﻻﺳﺘﺨﺪام ﺑﻌﺪ ﺗﺎرﯾﺦ اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ اﻟﻤﻄﺒﻮع ﻋﻠﻰ اﻟﻌﺒﻮة اﻟﺨﺎرﺟﯿﺔ. ﯾﺸﯿﺮ ﺗﺎرﯾﺦ اﻧﺘﮭﺎء اﻟﺼﻼﺣﯿﺔ إﻟﻰ آﺧﺮ ﯾﻮم ﻣﻦ اﻟﺸﮭﺮ.</p><p>&nbsp;</p><p dir="RTL"><strong>إرﺷﺎدات اﻟﺘﺨﺰﯾﻦ</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﯾُﺨﺰنﻓﻲ اﻟﺜﻼﺟﺔ )ﻓﻲ درﺟﺔ ﺣﺮارة ﺗﺘﺮاوح ﻣﻦ 2 إﻟﻰ 8 درﺟﺎت ﻣﺌﻮﯾﺔ.(</p><p dir="RTL">ﯾﺨﺰنﻓﻲ اﻟﻌﺒﻮة اﻷﺻﻠﯿﺔ ﻟﻠﺤﻤﺎﯾﺔ ﻣﻦ اﻟﺮطﻮﺑﺔ.</p><p>&nbsp;</p><p dir="RTL">ﯾﺠﺐ أن ﯾﻜﻮن اﻟﻤﻨﺘﺞﻓﻲ درﺟﺔ ﺣﺮارة اﻟﻐﺮﻓﺔ ﻗﺒﻞ اﻟﺤﻘﻦ. أﺧﺮﺟﮫ ﻣﻦ اﻟﺜﻼﺟﺔ ﻗﺒﻞ اﻻﺳﺘﻌﻤﺎل ﺑـ 30 دﻗﯿﻘﺔ ﺗﻘﺮﯾﺒًﺎ.</p><p dir="RTL">ﺑﻌد إﺧراﺟﮫ ﻣن اﻟﺛﻼﺟﺔ، ﻣن اﻟﻣﻣﻛن ﺣﻔظﮫ ﺑﻌﻠﺑﺗﮫ اﻷﺻﻠﯾﺔ ﺑدرﺟﺔ ﺣرارة دون C 25 ﻟﻣدة 4 أﺳﺎﺑﯾﻊ.</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">ﺑﻌﺪ ﻓﺘﺢ اﻟﻜﯿﺲ اﻟﻜﺒﯿﺮ اﻟﻤﺼﻨﻮع ﻣﻦ اﻷﻟﻮﻣﻨﯿﻮم أو اﻟﻌﺒﻮة اﻟﻤﺴﻄﺤﺔ، ﯾﺠﺐ ﺗﺤﻀﯿﺮ اﻟﻤﻨﺘﺞ ﻣﺒﺎﺷﺮة واﺳﺘﻌﻤﺎﻟﮫﻓﻲ اﻟﺤﺎل. ﻟﻼﺳﺘﺨﺪام ﻟﻤﺮة واﺣﺪة ﻓﻘﻂ.</p><p>&nbsp;</p><p dir="RTL"><strong>إرﺷﺎدات ﺣﻮل اﻟﺘﺨﻠﺺ ﻣﻦ ﻋﺒﻮات</strong><strong> ELIGARD</strong><strong> ﻏﯿﺮ اﻟﻤﺴﺘﺨﺪﻣﺔ أو ﻣﻨﺘﮭﯿﺔ اﻟﺼﻼﺣﯿﺔ</strong></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">ﻻ ﯾﺠﺐ اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ ﺑﺈﻟﻘﺎﺋﮭﺎ ﻓﻲ ﻣﯿﺎه اﻟﺼﺮف أو اﻟﻤﺨﻠﻔﺎت اﻟﻤﻨﺰﻟﯿﺔ. وﻟﻜﻦ اﺳﺄل اﻟﺼﯿﺪﻟﻲ ﻋﻦ ﻛﯿﻔﯿﺔ اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﯾﺔ اﻟﺘﻲ ﻟﻢ ﺗﻌﺪ</p><p>ھﻨﺎك ﺣﺎﺟﺔ إﻟﯿﮭﺎ.ﻓﺴﻮف ﺗﺴﺎﻋﺪ ھﺬه اﻹﺟﺮاءات ﻋﻠﻰ ﺣﻤﺎﯾﺔ اﻟﺒﯿﺌﺔ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">اﻟﻤﺎدة اﻟﻔﻌﺎﻟﺔ ھﻲ أﺳﯿﺘﺎت اﻟﻠﯿﻮﺑﺮورﻟﯿﻦ.</p><p dir="RTL">ﺣﻘﻨﺔ واﺣﺪة ﻣﻤﻠﻮءة ﻣﺴﺒﻘًﺎ )ﻣﺤﻘﻨﮫ ب( ﺗﺤﺘﻮى ﻋﻠﻰ 22.5 ﻣﻠﺠﻢ ﻣﻦ أﺳﯿﺘﺎت اﻟﻠﯿﻮﺑﺮورﻟﯿﻦ.</p><p dir="RTL">اﻟﻤﻜﻮﻧﺎت اﻷﺧﺮى ھﻲ ﻣﺎدة ﺑﻮﻟﻲ )ﺣﻤﺾ دي إل اﻟﻼﻛﺘﯿﻚ ﻣﻊ ﺣﻤﺾ اﻟﺠﻠﯿﻜﻮﻟﯿﻚ( (75:25) وﻣﺎدة إن-ﻣﯿﺜﯿﻞ-2-ﺑﯿﺮوﻟﯿﺪونﻓﻲ اﻟﻤﺤﻘﻨﺔ اﻟﻤﻤﻠﻮءة</p><p dir="RTL">ﻣﺴﺒﻘًﺎ ﺑﻤﺤﻠﻮل اﻟﺤﻘﻦ )ﻣﺤﻘﻨﺔ أ.(</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">دواء ELIGARD ﻋﺒﺎرة ﻋﻦ ﻣﺴﺤﻮق وﻣﺬﯾﺐ ﻟﻤﺤﻠﻮل اﻟﺤﻘﻦ. ﯾﺘﻮﻓﺮ دواء ELIGARD 22.5 ﻣﻠﺠﻢ ﻓﻲ اﻟﻌﺒﻮات اﻟﺘﺎﻟﯿﺔ</p><p dir="RTL">&middot;&nbsp;&nbsp; ﻋﺒﻮة ﻛﯿﺲ ﻋﺒﺎرة ﻋﻦ ﻛﯿﺲ ﺧﺎرﺟﻲ ﻛﺒﯿﺮ ﻣﺼﻨﻮع ﻣﻦ اﻷﻟﻮﻣﻨﯿﻮم ﺑﮫ ﻛﯿﺴﺎن ﻣﻦ اﻷﻟﻮﻣﻨﯿﻮم وإﺑﺮة ﻣﻌﻘﻤﺔ ﻣﻘﺎس 20 وﻛﯿﺲ ﻣﺠﻔﻒ. ﯾﺤﺘﻮى أﺣﺪ</p><p dir="RTL">اﻟﻜﯿﺴﯿﻦ ﻋﻠﻰ ﻣﺤﻘﻨﺔ )أ( ﻣﻦ اﻟﺒﻮﻟﻲ ﺑﺮوﺑﯿﻠﯿﻦ ﻣﻤﻠﻮءة ﻣﺴﺒﻘًﺎ وذراع ﻛﺒﺲ ﻛﺒﯿﺮ ﻟﻠﻤﺤﻘﻨﺔ )ب.( وﯾﺤﺘﻮي اﻟﻜﯿﺲ اﻵﺧﺮ ﻋﻠﻰ ﻣﺤﻘﻨﺔ )ب( ﻣﻦ اﻟﺒﻮﻟﻲ</p><p dir="RTL">ﺑﺮوﺑﯿﻠﯿﻦ ﻣﻤﻠﻮءة ﻣﺴﺒﻘًﺎ.</p><p dir="RTL">&middot; &nbsp;&nbsp;ﻋﻠﺒﺔ ﻋﺒﻮات ﻣﺴﻄﺤﺔ ﻣﺼﻨﻮﻋﺔ ﺑﺎﻟﺘﺸﻜﯿﻞ اﻟﺤﺮاري ﻋﺒﺎرة ﻋﺒﻮﺗﯿﻦ ﻣﺴﻄﺤﺘﯿﻦ ﻣﺼﻨﻮﻋﺘﯿﻦ ﺑﺎﻟﺘﺸﻜﯿﻞ اﻟﺤﺮاري داﺧﻞ ﻋﻠﺒﺔ ﻣﻦ اﻟﻮرق اﻟﻤﻘﻮى.</p><p dir="RTL">ﺗﺤﺘﻮي إﺣﺪى اﻟﻌﺒﻮﺗﯿﻦ ﻋﻠﻰ ﻣﺤﻘﻨﺔ )أ( ﻣﻦ اﻟﺒﻮﻟﻲ ﺑﺮوﺑﯿﻠﯿﻦ ﻣﻤﻠﻮءة ﻣﺴﺒﻘًﺎ وذراع ﻛﺒﺲ ﻛﺒﯿﺮ ﻟﻠﻤﺤﻘﻨﺔ )ب( وﻛﯿﺲ ﻣﺠﻔﻒ. وﺗﺤﺘﻮي اﻟﻌﺒﻮة اﻷﺧﺮى</p><p dir="RTL">ﻋﻠﻰ ﻣﺤﻘﻨﺔ )ب( ﻣﻦ اﻟﺒﻮﻟﻲ ﺑﺮوﺑﯿﻠﯿﻦ ﻣﻤﻠﻮءة ﻣﺴﺒﻘًﺎ وإﺑﺮة ﻣﻌﻘﻤﺔ ﻣﻘﺎس 20 وﻛﯿﺲ ﻣﺠﻔﻒ. &middot;&nbsp;&nbsp; ﻋﺒﻮة ﺣﺰﻣﺔ ﺗﺤﺘﻮي ﻋﻠﻰ ﻣﺠﻤﻮﻋﺎت ﻣﻦ 2 &times; 2 ﻣﻦ ﻣﺤﻘﻨﺎت ﻣﻤﻠﻮءة ﻣﺴﺒﻘًﺎ ﻣﺼﻨﻮﻋﺔ ﻣﻦ اﻟﺒﻮﻟﻲ ﺑﺮوﺑﯿﻠﯿﻦ )ﻣﺤﻘﻨﺔ أ واﺣﺪة وﻣﺤﻘﻨﺔ ب واﺣﺪة(</p><p>&nbsp;</p><p dir="RTL">ﻗﺪ ﻻ ﺗﺘﻮﻓﺮ ﺟﻤﯿﻊ أﺣﺠﺎم اﻟﻌﺒﻮات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>ﻣﺎﻟﻚ ﺣﻖ اﻟﺘﻔﻮﯾﺾ ﺑﺎﻟﺘﺴﻮﯾﻖ</strong> :</p><p>Astellas Pharma Europe B.V.</p><p>Sylviusweg 62</p><p>2333 BE Leiden</p><p dir="RTL">ھﻮﻟﻨﺪا</p><p>&nbsp;</p><p dir="RTL"><strong>اﻟﻤﺼﻨﻌﻮن</strong></p><p>Tolmar Inc. 701 Centre Avenue Ft. Collins, CO 80526</p><p dir="RTL">اﻟﻮﻻﯾﺎت اﻟﻤﺘﺤﺪة</p><p>&nbsp;</p><p>Cangene bioPharma Inc. 1111 South Paca Street Baltimore,&nbsp; MD 21230</p><p dir="RTL">اﻟﻮﻻﯾﺎت اﻟﻤﺘﺤﺪة</p><p>&nbsp;</p><p dir="RTL"><strong>اﻟﺸﺮﻛﮫ اﻟﻤﺴﺆوﻟﮫ ﻋﻦ إﺟﺎزه اﻟﺘﺸﻐﯿﻼت</strong></p><p>Astellas Pharma Europe B.V.</p><p>Sylviusweg 62</p><p>2333 BE Leiden</p><p dir="RTL">ھﻮﻟﻨﺪا</p><p>&nbsp;</p><p dir="RTL"><strong>ﻋﻨﻮان اﻟﻤﺼﻨﻊ</strong></p><p>Astellas Pharma Europe B.V.</p><p>Hogemaat 2</p><p>7942 JG Meppel</p><p dir="RTL">ھﻮﻟﻨﺪا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            آﺧﺮ ﻣﺮاﺟﻌﺔ ﻟﮭﺬه اﻟﻨﺸﺮة ﻓﻲ ﺗﺷرﯾن اﻟﺛﺎﻧﻲ / ﻧوﻓﻣﺑر .2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ELIGARD  22.5 mg powder and solvent for solution for  injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One prefilled syringe with powder for solution for injection contains 22.5 mg leuprorelin acetate, equivalent  to 20.87 mg leuprorelin.

For a full list  of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder and solvent for solution for injection, Powder (Syringe B):
Pre-filled  syringe with a white to off-white powder.

Solvent (Syringe A):
Pre-filled syringe with a clear, colourless to pale yellow   solution

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ELIGARD 22.5 mg is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em>Adult Males</em></p><p><em>&nbsp;</em></p><p>ELIGARD should be administered under the direction of a healthcare professional having available the appropriate expertise for monitoring the response to treatment.</p><p>&nbsp;</p><p>ELIGARD 22.5 mg is administered as a single subcutaneous injection every three months. The injected solution forms a solid medicinal product delivery depot and provides continuous release of leuprorelin acetate over a three-month period.</p><p>&nbsp;</p><p>As a rule, therapy of advanced prostate cancer with ELIGARD 22.5 mg entails long-term treatment and therapy should not be discontinued when remission or improvement occurs.</p><p>&nbsp;</p><p>ELIGARD 22.5 mg may be used as neoadjuvant or adjuvant therapy in combination with radiotherapy in&nbsp; high-risk localised&nbsp; and locally&nbsp; advanced prostate cancer.</p><p>&nbsp;</p><p>Response to ELIGARD&nbsp; 22.5 mg should be monitored by clinical&nbsp; parameters and by measuring prostate specific antigen (PSA) serum levels. Clinical studies have shown that testosterone levels increased during the first 3 days of treatment in the majority of non-orchiectomised patients and then decreased to below medical castration levels within 3 - 4 weeks. Once attained, castrate levels were maintained as long as medicinal product therapy continued (&lt; 1% testosterone breakthroughs). In case the patient&rsquo;s response appears to be sub-optimal, it should be confirmed that serum testosterone levels have reached or are remaining at castrate levels. As lack of efficacy may result from &nbsp;incorrect</p><p>&nbsp;</p><p>&nbsp;</p><p>preparation, reconstitution, or administration, testosterone levels should be evaluated in cases of suspected or known handling errors (see section 4.4).</p><p>&nbsp;</p><p>In patients with metastatic castration resistant prostate cancer not surgically castrated receiving a&nbsp; GnRH agonist, such as leuprorelin, and eligible for treatment with androgen biosynthesis inhibitors or androgen receptor inhibitors, treatment with a GnRH agonist may be continued.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p><em>&nbsp;</em></p><p>Safety and efficacy in children aged 0 to 18 years have not been established (see also section&nbsp; 4.3).</p><p>&nbsp;</p><p><em>Specific Patient Populations</em></p><p><em>&nbsp;</em></p><p>No clinical studies were performed in patients with either liver or kidney impairment. <u>Method of administration</u></p><p>ELIGARD&nbsp; 22.5 mg should be prepared, reconstituted and administered only by healthcare professionals who are familiar with these procedures. See section 6.6: Special precautions for disposal and other handling.&nbsp; If the product is not prepared appropriately, it should not be &nbsp;administered.</p><p>&nbsp;</p><p>The contents of the two pre-filled sterile syringes must be mixed immediately prior to administration of ELIGARD&nbsp; 22.5 mg by subcutaneous injection.</p><p>&nbsp;</p><p>Based on data from animal experience, intra-arterial or intravenous injection, respectively, has to be strictly avoided.</p><p>&nbsp;</p><p>As with other medicinal products administered by subcutaneous injection, the injection site should be varied periodically.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ELIGARD  22.5 mg is contraindicated in women and paediatric  patients.
Hypersensitivity to leuprorelin acetate, to other GnRH agonists or to any of the excipients listed in section 6.1.

In patients who previously underwent orchiectomy (as with other GnRH agonists, ELIGARD 22.5 mg does not result in  further decrease of serum testosterone in case of surgical castration).

As sole treatment in prostate cancer patients with spinal cord compression or evidence of spinal metastases (see also section 4.4)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Correct reconstitution: </u>Lack of clinical efficacy may occur due to incorrect reconstitution of the product. See section 4.2 and section 6.6 for the instructions for preparation and administration of the product and for evaluation&nbsp; of testosterone levels in&nbsp; cases of suspected or known handling &nbsp;errors.</p><p>&nbsp;</p><p><u>Androgen deprivation&nbsp; therapy may prolong the QT interval:</u></p><p>In patients with a history of or risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval (see section 4.5) physicians should assess the benefit&nbsp; risk ratio including&nbsp; the potential for Torsade de pointes prior to initiating&nbsp; ELIGARD&nbsp; 22.5 mg.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Cardiovascular diseases: </u>Increased risk of developing myocardial infarction, sudden cardiac death and stroke has been reported in association with use of GnRH agonists in men. The risk appears low based on the reported odds ratios, and should be evaluated carefully along with cardiovascular risk factors when determining a treatment for patients with prostate cancer. Patients receiving GnRH agonists should be monitored for symptoms and signs suggestive of development of cardiovascular disease and be managed according to current clinical practice.</p><p><u>Transient testosterone flare: </u>Leuprorelin acetate, like&nbsp; other GnRH agonists, causes a transient increase&nbsp; in serum concentrations of testosterone, dihydrotestosterone and acid phosphatase during the first week of treatment. Patients may experience worsening of symptoms or onset of new symptoms, including bone pain, neuropathy, haematuria, or ureteral or bladder outlet obstruction (see section 4.8). These symptoms usually subside on continuation of therapy.</p><p>&nbsp;</p><p>Additional administration of an appropriate antiandrogen should be considered beginning 3 days prior&nbsp; to leuprorelin therapy and continuing for the first two to three weeks of treatment. This has been reported to prevent the sequelae of an initial&nbsp; rise in&nbsp; serum testosterone.</p><p>&nbsp;</p><p>Following surgical castration, ELIGARD 22.5 mg does not lead to a further decrease in serum testosterone levels in&nbsp; male patients.</p><p>&nbsp;</p><p><u>Bone density: </u>Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with GnRH agonists (see section 4.8).</p><p>Antiandrogen therapy significantly increases the risk for fractures owing to osteoporosis. Only limited data is available on this issue. Fracturesowing to osteoporosis were observed in 5% of patients following 22 months of pharmacological androgen deprivation therapy and in 4% of patients following 5 to 10 years of treatment. The risk for fractures owing to osteoporosis is generally higher than the risk for pathological fractures.</p><p>Apart from long lasting testosterone deficiency, increased age, smoking and consumption of alcoholic beverages, obesity and insufficient exercise may have an influence on the development of osteoporosis.</p><p>&nbsp;</p><p><u>Pituitary apoplexy: </u>During post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of GnRH-agonists, with a majority occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy was presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention is required.</p><p>&nbsp;</p><p><u>Hyperglycemia and diabetes: </u>Hyperglycemia and an increased risk of developing diabetes have been reported in men receiving GnRH agonists. Hyperglycemia may represent development of diabetes mellitus or worsening of glycemic control in patients with diabetes. Monitor blood glucose and/or glycosylated hemoglobin (HbA1c) periodically in patients receiving a GnRH agonist and manage with current practice for treatment of hyperglycemia or diabetes.</p><p><u>Convulsions: </u>Post marketing reports of convulsions have been observed in patients on leuprorelin acetate with or without a history of predisposing factors. Convulsions are to be managed according to the current clinical practice.</p><p><u>Other events: </u>Cases of ureteral obstruction and spinal cord compression, which may contribute to paralysis with or without fatal complications, have been reported with GnRH agonists. If spinal cord compression or renal impairment develops, standard treatment of these complications should be instituted.</p><p>Patients with vertebral and/or brain metastases as well as patients with urinary tract obstruction should be closely monitored during the first few weeks of therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No pharmacokinetic drug-drug interaction studies have been performed with ELIGARD 22.5 mg. There have been no reports of any interactions of leuprorelin acetate with other medicinal&nbsp; products.</p><p>&nbsp;</p><p>Since androgen deprivation&nbsp; treatment may prolong the QT interval, the concomitant use of ELIGARD</p><p>22.5 mg with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc. should be carefully evaluated&nbsp; (see section 4.4).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable&nbsp; as ELIGARD&nbsp; 22.5 mg is contraindicated in&nbsp; women.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects of ELIGARD 22.5 mg on the ability to drive and use machines have been performed.</p><p>The ability to drive and operate machines may be impaired due to fatigue, dizziness and visual disturbances being possible side effects of treatment or resulting from the underlying disease.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions seen with ELIGARD 22.5mg are mainly subject to the specific pharmacological action of leuprorelin acetate, namely increases and decreases in certain hormone levels. The most commonly reported adverse reactions are hot flashes, nausea, malaise and fatigue and transient local irritation&nbsp; at the site of injection.&nbsp; Mild&nbsp; hot flashes occur in approximately 58% of patients.</p><p>&nbsp;</p><p><u>Tabulated list&nbsp; of adverse reactions</u></p><p>The following adverse events were reported during clinical trials with ELIGARD in patients with advanced prostatic carcinoma. Adverse events are classified, by frequency, as very common (&sup3;1/10), common (&sup3;1/100, &lt;1/10), uncommon (&sup3;1/1,000, &lt;1/100), rare (&sup3;1/10,000, &lt;1/1,000), and very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><em>Table 1</em><strong>: <em>Undesirable effects inclinical studies with Eligard</em></strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>nasopharyngitis</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>urinary tract infection, local skin infection</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>aggravateddiabetes mellitus</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Psychiatric&nbsp; disorders</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>abnormaldreams, depression, decreased libido</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p><strong>Nervous systemdisorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>dizziness, headache, hypoaesthesia, insomnia, taste disturbance, smell disturbance, vertigo</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>abnormalinvoluntarymovements</p></td></tr><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p><p>not known</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>QT prolongation (see sections 4.4 and 4.5)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>hot flashes</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>hypertension,&nbsp; hypotension</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>syncope, collapse</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, </strong><strong>thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><em>Table 1</em><strong>: <em>Undesirable effects inclinical studies with Eligard</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>rhinorrhoea, dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal&nbsp; disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>nausea, diarrhoea, gastroenteritis/colitis</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>constipation, dry mouth, dyspepsia ,vomiting</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>flatulence, eructation,</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>ecchymoses, erythema</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>pruritus, night sweats</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>clamminess, increased sweating</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>alopecia, skin eruption</p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; connective&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tissues disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>arthralgia, limb pain, myalgia, rigors, weakness</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>backpain, muscle cramps</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinarydisorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>urinary infrequency, difficulty in micturation, dysuria, nocturia, oliguria</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>bladder spasm, haematuria, aggravated urinaryfrequency, urinary retention</p></td></tr><tr><td style="vertical-align:top"><p><strong>Reproductive systemand breast disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>breast tenderness, testicular atrophy, testicular pain</p><p>infertility, breast hypertrophy, erectile dysfunction, reduced penis size</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>gynaecomastia, impotence, testicular disorder</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>breast pain</p></td></tr><tr><td style="vertical-align:top"><p><strong>General</strong><strong> </strong><strong>disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>fatigue, injection site burning, injection site paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>Malaise,injection site pain, injection site bruising, injection site stinging</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>injection site pruritus, injection site induration, lethargy, pain, pyrexia</p></td></tr><tr><td style="vertical-align:top"><p>rare</p></td><td style="vertical-align:top"><p>injection site ulceration</p></td></tr><tr><td style="vertical-align:top"><p>very rare</p></td><td style="vertical-align:top"><p>injection site necrosis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Blood and lymphatic systemdisorders</strong></p></td><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p><p>hematologychanges, anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>increasedbloodcreatininephosphokinase, prolonged coagulation time</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>increasedalanine aminotransferase, increasedbloodtriglycerides, prolonged&nbsp; prothrombintime, increasedweight</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>Other adverse events which have been reported in general to occur with leuprorelin acetate treatment include peripheral oedema, pulmonary embolism, palpitations, myalgia, muscle weakness, an alteration in the skin sensation, chills, rash, amnesia and visual disturbances. Muscular atrophy has been observed with long term use of products in this class. Infarction of pre-existing pituitary apoplexy has been reported rarely after administration of both short and long acting GnRH agonists. There have been rare reports of thrombocytopenia and leucopenia. Changes in glucose tolerance have been reported.</p><p>&nbsp;</p><p>Convulsions have been reported after GnRH agonist analogue administration&nbsp; (see section 4.4).</p><p>&nbsp;</p><p>Local adverse events reported after injection of ELIGARD are similar to the local adverse events associated with similar&nbsp; subcutaneously injected products.</p><p>&nbsp;</p><p>&nbsp;</p><p>Generally, these localised adverse events following subcutaneous injection are mild and described as being of brief duration.</p><p>&nbsp;</p><p>Anaphylactic/anaphylactoid reactions have been reported rarely after GnRH agonist analogue administration.</p><p>&nbsp;</p><p><u>Changes in Bone Density</u></p><p>Decreased bone density has been reported in the medical literature in men who have had orchiectomy&nbsp; or who have been treated with GnRH analogues. It can be anticipated that long periods of treatment with leuprorelin may show increasing signs of osteoporosis. Regarding the increased risk for fractures owing to osteoporosis (see section 4.4).</p><p>&nbsp;</p><p><u>Exacerbation of signs and symptoms of the disease</u></p><p>Treatment with leuprorelin acetate can cause exacerbations of signs and symptoms of the disease during the first few weeks. If conditions such as vertebral metastases and/or urinary obstruction or haematuria are aggravated, neurological problems such as weakness and/or paraesthesia of the lower limbs or worsening of urinary symptoms may occur.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse&nbsp; reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>ELIGARD 22.5mg does not have the potential for abuse, and deliberate overdose is unlikely. There are no reports of abuse or overdose having occurred in clinical practice with leuprorelin acetate, but in the event that excessive exposure becomes a reality, observation and symptomatic supportive treatment are recommended.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Gonadotropin releasing hormone analogues ATC code: L02A E02</p><p>&nbsp;</p><p>Leuprorelin acetate is a synthetic nonapeptide agonist of naturally occurring gonadotropin releasing hormone (GnRH) that, when given continuously, inhibits pituitary gonadotropin secretion and suppresses testicular steroidogenesis in males. This effect is reversible upon discontinuation of medicinal product therapy. However, the agonist possesses greater potency than the natural hormone and the time to recovery of testosterone levels may vary between&nbsp; patients.</p><p>&nbsp;</p><p>Administration of leuprorelin acetate results in an initial increase in circulating levels of luteinising hormone (LH) and follicle stimulating hormone (FSH), leading to a transient increase in levels of the gonadal steroids, testosterone and dihydrotestosterone in males. Continuous administration of leuprorelin acetate results in decreased levels of LH and FSH. In males, testosterone is reduced to below castrate threshold (&le; 50 ng/dL). These decreases occur within three to five weeks after initiation of treatment. Mean testosterone levels at six months are 10.1 (&plusmn; 0.7) ng/dL, comparable to levels following bilateral orchiectomy. All patients who received the full dose of 22.5 mg leuprorelin in the pivotal&nbsp; clinical study reached castrate levels at 5 weeks; 99 % had reached this by day 28. In the vast majority&nbsp; of patients the testosterone levels seen were below 20 ng/dL although the full benefit of these low levels has not yet been established. PSA levels&nbsp; decreased by 98% over six &nbsp;months.</p><p>&nbsp;</p><p>&nbsp;</p><p>Long-term studies have shown that continuation of therapy maintains testosterone below the castrate level&nbsp; for up to seven years, and presumably indefinitely.</p><p>&nbsp;</p><p>Tumour size was not measured directly during the clinical trial programme, but there was an indirect beneficial tumour response as shown by a 98% reduction in mean PSA for ELIGARD&nbsp; 22.5 mg.</p><p>&nbsp;</p><p>In a phase III randomized clinical trial including 970 patients with locally advanced prostate cancer (mainly T2c-T4 with some T1c to T2b patients with pathological regional nodal disease) of whom 483 were assigned to short-term androgen suppression (6 months) in combination with radiation therapy and 487 to long-term therapy (3 years), a non-inferiority analysis compared the short-term to long-term concomitant and adjuvant hormonal treatment with GnRH agonist (triptorelin or goserelin). The 5-year overall mortality was 19.0% and 15.2%, in the short-term and long-term groups, respectively. The observed Hazard Ratio of 1.42 with an upper one-sided 95.71% CI of 1.79 or two-sided 95.71% CI of 1.09; 1.85 (p = 0.65 for non inferiority), demonstrate that the combination of radiotherapy plus 6 months of androgen deprivation therapy provides inferior survival as compared with radiotherapy plus 3 years of androgen deprivation therapy. Overall survival at 5 years of long-term treatment and short-term treatment shows 84.8% survival and 81.0%, respectively. Overall quality of life using QLQ-C30 did not differ significantly between the two groups (P= 0.37). Results are dominated by the population of patients with locally&nbsp; advanced tumours.</p><p>&nbsp;</p><p>Evidence for the indication of high-risk localized prostate cancer is based on published studies of radiotherapy combined with GnRH analogues, including leuprorelin acetate. Clinical data from five published studies were analyzed (EORTC 22863, RTOG 85-31, RTOG 92-02, RTOG 8610, and D&rsquo;Amico et al., JAMA, 2004), which all demonstrate a benefit for the combination of GnRH analogue with radiotherapy. Clear differentiation of the respective study populations for the indications locally advanced prostate cancer and high-risk localized prostate cancer was not possible in the published studies.</p><p>&nbsp;</p><p>Clinical data have shown that radiotherapy followed by 3 years of androgen deprivation therapy is preferable to radiotherapy followed by 6 months of androgen deprivation therapy.</p><p>The recommended duration of androgen deprivation therapy in medical guidelines for T3-T4 patients receiving&nbsp; radiotherapy is 2-3 years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption: In patients with advanced carcinoma of the prostate, mean serum leuprorelin concentrations following the initial&nbsp; injection&nbsp; rise to 127ng/ml at&nbsp; 4.6 hr (Cmax) after injection. After&nbsp; the initial increase following each injection (the plateau phase from 3 - 84 days after each dose), serum concentrations remained relatively constant (0.2 &ndash; 2 ng/ml). There is no evidence of accumulation during repeated dosing.</p><p>&nbsp;</p><p>Distribution: The mean steady-state volume of distribution of leuprorelin following intravenous bolus administration to healthy male volunteers was 27 litres. <em>In vitro </em>binding to human plasma proteins ranged from 43% to 49%.</p><p>&nbsp;</p><p>Elimination:&nbsp; In healthy&nbsp; male volunteers, a 1 mg bolus of leuprorelin&nbsp; acetate administered&nbsp; intravenously revealed that the mean systemic clearance was 8.34 l/h, with a terminal elimination half- life&nbsp; of approximately 3 hours based on a two compartment model.</p><p>&nbsp;</p><p>No excretion studies have been conducted with ELIGARD. No drug metabolism study was conducted with&nbsp; ELIGARD.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical studies with leuprorelin acetate, revealed in both sexes effects on the reproductive system, which were expected from the known pharmacological properties. These effects were shown to be reversible after discontinuation of the treatment and an appropriate period of regeneration. Leuprorelin acetate did not show teratogenicity. Embryotoxicity/lethality was observed in rabbits, in line with the pharmacological effects of leuprorelin acetate on the reproductive system.</p><p>&nbsp;</p><p>Carcinogenicity studies were performed in rats and mice over 24 months. In rats, a dose-related increase in pituitary apoplexy was observed after subcutaneous administration at doses of 0.6 to 4 mg/kg/day. No such effect was observed in mice.</p><p>&nbsp;</p><p>Leuprorelin acetate and related&nbsp; one-month product ELIGARD 7.5 mg were not mutagenic in a set of in vitro and in vivo&nbsp; assays.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Solvent (syringe A):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Poly&nbsp; (DL-lactic-co-glycolic-acid) (75:25)</p><p>N-Methylpyrrolidone Powder (syringe B):&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; None</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The leuprorelin present in syringe B must only be mixed with the solvent in syringe A and must not be mixed&nbsp; with other medicinal products.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
Once the product has been removed from the refrigerator, it may be stored in the original packaging at room temperature (below 25°C) for up to four weeks.

After first opening of the tray, the powder and solvent for solution for injection are to be immediately reconstituted and administered to the patient.

Once reconstituted: use immediately, as the viscosity of the solution increases with  time.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C &ndash; 8&deg;C); in the original package in order to protect from moisture. This product must be at room temperature prior to injection. Remove from the refrigerator approximately 30 minutes before use. Once outside the refrigerator this product may be stored in its original packaging at room temperature (below 25&deg;C) for up to four&nbsp; weeks.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Two syringes, one cyclic olefin copolymer syringe containing powder (Syringe B), and one polypropylene syringe containing solvent (Syringe A). Together the two syringes comprise a mixing system.</p><p>&nbsp;</p><p>&nbsp;</p><p>Syringe A has a plunger tip of thermoplastic rubber and is capped with a polyethylene or polypropylene Luer Lock cover. The syringe tip cap and the two plunger tips of Syringe B are composed of chlorobutyl rubber.</p><p>&nbsp;</p><p>The following&nbsp; pack sizes are available:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A kit consisting of two thermoformed trays in a cardboard carton. One tray contains one pre- filled polypropylene syringe A, a large plunger rod and a desiccant pouch. The other tray contains pre-filled cyclic olefin copolymer syringe B, a 20-gauge sterile needle and a silicone desiccant pouch.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A bundle pack containing kits of 2 x 2 syringes (1 x Syringe A; 1 x Syringe B) Not all&nbsp; pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Allow the product to come to room temperature by removing fromthe refrigerator approximately 30 minutes prior to use.</strong></p><p><strong>Please prepare the patient for injection first, followed by the preparation of the product,&nbsp; using</strong></p><p><strong>the instructions below. If the product is not prepared using the proper technique, it should not be administered, as lack of clinical efficacy may occur due to incorrect reconstitution of the product.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Step 1: </strong>Open both trays (tear off the foil from the corner which can be recognized by a small bubble) and empty the contents onto a clean field (two trays containing Syringe A (Figure 1.1) and Syringe B (Figure 1.2)). Discard the desiccant pouches.</p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image1.jpeg" o:spid="_x0000_s1039" type="#_x0000_t75"
  alt="Macintosh HD:Users:Beheer:Desktop:1.1_1.2 16-51-09.jpg" style='position:absolute;
  margin-left:72.4pt;margin-top:12.7pt;width:456.7pt;height:85.45pt;z-index:251658240;
  visibility:visible;mso-wrap-style:square;mso-wrap-distance-left:0;
  mso-wrap-distance-top:0;mso-wrap-distance-right:0;mso-wrap-distance-bottom:0;
  mso-position-horizontal:absolute;mso-position-horizontal-relative:page;
  mso-position-vertical:absolute;mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
   o:title="1.1_1.2 16-51-09"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><strong>Step 2: <u>Pull out </u></strong>and <strong>do not unscrew </strong>the blue coloured short plunger rod together with the attached grey stopper from Syringe B and discard (Figure 2). <strong>Do not attempt to mix the product with two stoppers in place.</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image2.jpeg" o:spid="_x0000_s1038" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:2.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:13.95pt;width:232.35pt;
  height:88.7pt;z-index:1048;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
   o:title="2"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 3: </strong>Gently screw the Syringe B white plunger rod to the remaining grey stopper in Syringe B (Figure 3).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image3.jpeg" o:spid="_x0000_s1037" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:3.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.95pt;width:231.35pt;
  height:88.7pt;z-index:1072;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image005.jpg"
   o:title="3"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><strong>Step 4: </strong>Remove the grey rubber cap from Syringe Band put down the Syringe (Figure 4).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image4.jpeg" o:spid="_x0000_s1036" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:4.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.8pt;width:236.9pt;
  height:90.4pt;z-index:1096;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image007.jpg"
   o:title="4"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 5: </strong>Hold Syringe A in a vertical position to ensure no liquid leaks out and unscrew the clear cap from Syringe A (Figure 5).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image5.jpeg" o:spid="_x0000_s1035" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:5.jpg"
  style='position:absolute;margin-left:77.9pt;margin-top:12.7pt;width:115.8pt;
  height:202.6pt;z-index:1120;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image009.jpg"
   o:title="5"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 6: </strong>Join the two syringes together by pushing in and twisting Syringe Bonto Syringe A until secure (Figure 6a and 6b). <strong>Do not over tighten</strong>.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image6.jpeg" o:spid="_x0000_s1034" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:6.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.95pt;width:231.05pt;
  height:202.2pt;z-index:1144;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image011.jpg"
   o:title="6"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p><strong>Step 7: </strong>Flip the connected unit over and continue to hold the syringes vertically with Syringe B on the bottom while injecting the liquid contents of Syringe A into Syringe B containing the&nbsp; powder (leuproreline&nbsp; acetate) (Figure 7).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image7.jpeg" o:spid="_x0000_s1033" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:7.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.7pt;width:111.35pt;
  height:194.7pt;z-index:1168;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image013.jpg"
   o:title="7"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 8: </strong>Thoroughly mix the product by gently pushing the contents of both syringes back and forth between syringes (60 times in total, which takes approximately 60 seconds) in a horizontal position to obtain a homogenous, viscous solution (Figure 8). Do not bend the syringe system (please note that this may cause leakage as you may partially&nbsp; unscrew the syringes).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image8.jpeg" o:spid="_x0000_s1032" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:8.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:13.1pt;width:236.95pt;
  height:87.8pt;z-index:1192;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image015.jpg"
   o:title="8"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>When thoroughly mixed, the viscous solution will appear with a colour in the range of colourless to white to pale yellow (which could include shades of white to pale yellow).</p><p><strong>&nbsp;</strong></p><p><strong>Important: After mixing proceed with the next step immediately as the product gets more viscous over time. Do not refrigerate the mixed product.</strong></p><p><strong>&nbsp;</strong></p><p>Please note: Product must be mixed as described; shaking WILL NOT provide adequate mixing of the product.</p><p>&nbsp;</p><p><strong>Step 9: </strong>Hold the syringes vertically with Syringe B on the bottom. The syringes should remain securely coupled. Draw the entire mixed product into Syringe B (short, wide syringe) by pushing down the Syringe A plunger and slightly&nbsp; withdrawing the Syringe B plunger (Figure 9).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image9.jpeg" o:spid="_x0000_s1031" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:9.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.7pt;width:114.5pt;
  height:199pt;z-index:1216;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image017.jpg"
   o:title="9"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 10: </strong>Twist off Syringe A while continuing to push down on the Syringe A plunger (Figure 10). Ensure that no product leaks out as the needle will then not secure properly when attached.</p><p>&nbsp;</p><p>Please note: one large or a few small air&nbsp; bubbles&nbsp; may remain in the formulation - this is acceptable.</p><p>Please do not purge the air bubbles from Syringe B at this stage as product may be&nbsp;&nbsp; lost!</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image10.jpeg" o:spid="_x0000_s1030" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:10.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.8pt;width:107.8pt;
  height:189.65pt;z-index:1240;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image019.jpg"
   o:title="10"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 11:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hold&nbsp; Syringe B upright and hold back the white plunger to prevent loss of the product.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Open pack of the safety needle by peeling&nbsp; back paper tab and take out safety needle.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Secure the safety needle to Syringe B by holding the syringe and gently turning the needle clockwise with approximately a three-quarter turn until the needle&nbsp; is&nbsp; secure (Figure 11).</p><p><strong>Do not over tighten </strong>as this may cause cracking of the needle hub resulting in leakage of the product during injection.</p><p>&nbsp;</p><p>Should the needle hub crack, appear to be damaged, or have any leakage, the product should not be used. The damaged needle should not be substituted/replaced and the product should not be injected. The entire product should be disposed of securely</p><p>&nbsp;</p><p>In the event of damage to the needle hub, a new replacement product should be used.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image11.jpeg" o:spid="_x0000_s1029" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:11.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.25pt;width:113.25pt;
  height:199.3pt;z-index:1264;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image021.jpg"
   o:title="11"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 12: </strong>Pull off the protective needle cover prior to administration (Figure 12).</p><p>Important: Do not operate the safety needle mechanism before&nbsp; administration.</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image12.jpeg" o:spid="_x0000_s1028" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:12.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.85pt;width:117.95pt;
  height:205.6pt;z-index:1288;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image023.jpg"
   o:title="12"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 13: </strong>Prior to administration, purge any large air bubbles from Syringe B. Administer the product subcutaneously. Please ensure that the full amount of the product in Syringe B is injected.</p><p>&nbsp;</p><p><strong>Step 14: </strong>After injection,&nbsp; lock the safety shield&nbsp; using any of the activation methods listed below.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Closure on a flat surface</p><p><strong>&nbsp;</strong></p><p>Press the safety shield, lever side down, onto a flat surface (Figure 14.1a and b) to cover the needle and lock the shield.</p><p>Verify locked position through audible and tactile &ldquo;click&rdquo;. Locked position will completely cover needle tip&nbsp; (figure 14.1b).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image13.jpeg" o:spid="_x0000_s1027" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:14.1.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.7pt;width:232.3pt;
  height:193.2pt;z-index:1312;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image025.jpg"
   o:title="14.1"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Closure with your thumb</p><p><strong>&nbsp;</strong></p><p>Placing your thumb on the lever, slide the safety shield toward the needle tip (Figure 14.2a and b) to cover the needle and lock the shield.</p><p>Verify locked position through audible and tactile &ldquo;click&rdquo;. Locked position will completely cover needle tip&nbsp; (figure 14.2b).</p><p><!--[if gte vml 1]><o:wrapblock><v:shape
  id="image14.jpeg" o:spid="_x0000_s1026" type="#_x0000_t75" alt="Astellas:Astellas Algemeen:198111301_Astellas_Safety Needle:DTP:JPG:14.2.jpg"
  style='position:absolute;margin-left:72.4pt;margin-top:12.7pt;width:236.8pt;
  height:206.6pt;z-index:1336;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/EU9008~1/AppData/Local/Temp/msohtmlclip1/01/clip_image027.jpg"
   o:title="14.2"/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>&nbsp;</p><p><strong>Step 15</strong>: Once safety shield is locked, immediately dispose of the needle and syringe in an approved sharps container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Astellas  Pharma Europe B.V.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>